Production of laminar extrudates containing particles of a model drug processed by supercritical fluids by Oliveira, Gonçalo Emanuel Rodrigues da Cunha Correia de, 1983-
  
UNIVERSIDADE DE LISBOA 
FACULDADE DE FARMÁCIA 
DEPARTAMENTO DE FARMÁCIA GALÉNICA E TECNOLOGIA FARMACÊUTICA 
 
 
 
Production of laminar extrudates containing particles 
of a model drug processed by supercritical fluids 
 
 
Gonçalo Emanuel Rodrigues da Cunha Correia de Oliveira 
DOUTORAMENTO EM FARMÁCIA 
(Tecnologia Farmacêutica) 
 
Tese orientada pelo Professor Doutor João F. Pinto e coorientada pelo Professor Doutor Martin A. Wahl, 
especialmente elaborada para a obtenção do grau de doutor no ramo de Farmácia, 
Especialidade de Tecnologia Farmacêutica 
 
Lisboa, 2015  
  
 
  
UNIVERSIDADE DE LISBOA 
FACULDADE DE FARMÁCIA 
DEPARTAMENTO DE FARMÁCIA GALÉNICA E TECNOLOGIA FARMACÊUTICA 
 
 
 
Production of laminar extrudates containing particles 
of a model drug processed by supercritical fluids 
 
 
Gonçalo Emanuel Rodrigues da Cunha Correia de Oliveira 
DOUTORAMENTO EM FARMÁCIA 
(Tecnologia Farmacêutica) 
 
Tese orientada pelo Professor Doutor João F. Pinto e coorientada pelo Professor Doutor Martin A. Wahl, 
especialmente elaborada para a obtenção do grau de doutor no ramo de Farmácia, 
Especialidade de Tecnologia Farmacêutica 
 
Lisboa, 2015  
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A quem muito me amou, 
a quem muito me ama 
e a quem eu muito amo. 
 
  
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“O caminho para se conseguir a felicidade 
é fazer as outras pessoas felizes.” 
Baden-Powell 
 
  
  
 
7 
 
Acknowledgements 
 
Ao Professor Doutor João F. Pinto por me ter lançado o desafio de realizar 
este projeto de Doutoramento. Considero que esta experiência foi e será decisiva 
para o meu percurso profissional. Agradeço muito todo o seu empenho na 
orientação científica deste projeto e as longas horas que despendeu para me ajudar 
a progredir, pelo constante incentivo à melhoria, pelo permanente estímulo à procura 
da máxima qualidade e por me ter acompanhado sempre ao longo desta viagem. 
 
To Professor Dr. Martin A. Wahl for his co-supervision of this thesis. I have 
learned a lot while working directly with him and his constant support was essential 
for accomplishing my goals. Furthermore, all periods of work in Tübingen under his 
direct supervision were excellent learning occasions. 
 
To Kathrin Müllers for all the support while I was in Tübingen, especially all 
the help in the laboratorial experiments, the guidance, the friendship, and for the 
wonderful moments shared in Tübingen, in Lisbon and during our congress trips. 
 
À Doutora Maria Luísa Corvo por me ter acompanhado no decorrer dos 
estudos in-vivo. Foi incansável e agradeço toda a sua paciência e o entusiasmo com 
que me acolheu e me orientou na realização do trabalho. 
 
To Klaus Weyhing, Philipp Metzger, Roland Walker and Martina Brenn for all 
the support and help with the laboratorial activities developed in Tübingen. To Prof. 
Dr. Rolf Daniels for his kindness and for receiving me so well in his department. 
 
 
8 
 
À Sara Raposo, ao Rui Lopes, à Diana Rafael, à Joana Silva, à Joana Marto 
e à Maria de Fátima Pina, pelo apoio e amizade. Foi excelente poder partilhar este 
percurso na FFUL e desejo-lhes o máximo sucesso para as suas vidas pessoais e 
profissionais. 
 
Aos Professores Doutores António Almeida, Rogério Sá Gaspar, Helena 
Florindo, Helena Margarida Ribeiro, Helena Cabral Marques, Luís Gouveia e Andreia 
Ascenso, a às Doutoras Lídia Gonçalves e Liana Silva, por todos os momentos que 
tive a oportunidade de partilhar na FFUL, especialmente aqueles em que de algum 
modo me ajudaram a progredir e em que me transmitiram conhecimentos e uma 
parte da sua vasta experiência. 
 
Às Doutoras Maria Eugénia da Cruz, Sandra Simões, Maria Manuela Gaspar, 
Manuela Colla e Maria Bárbara Martins, pela simpatia com que sempre me 
receberam no Campus do Lumiar. Agradeço toda a disponibilidade e apoio que me 
ofereceram para que pudesse concluir o meu trabalho laboratorial com sucesso. 
 
À D. Fernanda Oliveira, à D. Henriqueta Pinto e à D. Fernanda Carvalho por 
todo o apoio, por toda a alegria e pela partilha de bons momentos no Pavilhão E ao 
longo deste anos. Desejo-lhes muitas felicidades! 
 
To Wolfgang and Sigrun Engelmann for sharing their house whenever I was 
in Tübingen. Their support was essential and I am very grateful for having the 
opportunity to meet them. 
 
À Mariana Paisana, à Íris Duarte, à Mariya Brachkova, à Ana Cristina Matos, 
à Inês Ferreira, à Liliana Caetano, ao Paulo Roque Lino, à Andreia Cordeiro, à 
9 
 
Etelvina Lapa, à Joana Pinto, ao André Couto, à Natália Vilaça, à Ana Raquel 
Varela, à Carina Peres e à Eva Zupancic, que de uma forma ou de outra se 
cruzaram comigo na FFUL durante os nosso percursos científicos. A todos desejo 
muito sucesso! 
 
While visiting Tübingen I had the opportunity to meet several scientists and 
PhD students to whom I wish all the best for their future, namely Khaled Hussein, 
Jutta Braun, Alexandra Baltisberger, Ragna Wischumerski, Stephan Maurath, 
Barbara Kannen, Patrick Rother, Sandra Barisch, Cornelia Witt, Marta Grysko, 
Annina Horst, Carsten Döhling, Dominique Lunter, Michael Rottke, Korbinian 
Schneider, Nelli Peters, and Cristhoph Rott. I thank them for the wonderful periods I 
had the opportunity to share with them in Tübingen. 
 
Agradeço à Faculdade de Farmácia da Universidade de Lisboa, ao 
iMed.ULisboa – Instituto de Investigação do Medicamento e a todos os seus 
responsáveis pela oportunidade que tive em me envolver em ambas as instituições. 
Ambas foram referências científicas muito importantes no meu percurso na medida 
em que me proporcionaram os ambientes necessários para o meu desenvolvimento 
a nível científico e também a nível pessoal. 
 
Agradeço à Fundação para a Ciência e a Tecnologia o financiamento do meu 
projeto de doutoramento através da atribuição de uma bolsa de doutoramento 
(SFRH/BD/39853/2007). 
 
À minha família, especialmente à minha mãe e ao meu irmão, agradeço todo 
o apoio, todo o amor e tudo o que têm feito por mim. São um pilar muito importante 
na minha vida. 
10 
 
Aos meus amigos agradeço-lhes a verdadeira amizade que temos vindo a 
construir ao longo dos tempos, iniciada em muitos dos casos muito antes do início 
deste projeto, e que estou certo perdurará para sempre. Esta amizade deu-me 
ânimo, alegria e vontade de querer mais e de alcançar os meus objetivos. 
 
 
Production of laminar extrudates containing particles of a model drug processed by supercritical fluids 
 
11 
 
TABLE OF CONTENTS 
 
Abstract ............................................................................................................. 19 
Resumo............................................................................................................. 23 
Abbreviations .................................................................................................... 29 
List of tables ...................................................................................................... 31 
List of figures ..................................................................................................... 33 
List of publications ............................................................................................. 37 
THESIS ........................................................................................................... 39 
1.  Challenges ............................................................................................ 41 
2.  Motivation and aim................................................................................. 41 
3.  Hypothesis ............................................................................................. 42 
4.  Research objectives and outcomes ....................................................... 42 
5.  Organization of the thesis ...................................................................... 43 
CHAPTER 1.................................................................................................... 45 
Introduction ................................................................................................... 45 
1.1.  Reduction of the size of particles ........................................................ 47 
1.1.1.  Top-down approaches .................................................................. 47 
1.1.2.  Bottom-up approaches .................................................................. 48 
1.1.2.1. Supercritical fluids techniques ................................................. 48 
1.2.  Rapid expansion of supercritical solutions (RESS) ............................. 49 
1.2.1.  Concept ........................................................................................ 49 
1.2.2.  Solvents used in RESS ................................................................. 50 
1.2.3.  Particle formation .......................................................................... 50 
1.2.4.  Process parameters influencing the properties of the particles ..... 51 
1.3.  Extrusion and co-extrusion ................................................................. 52 
Production of laminar extrudates containing particles of a model drug processed by supercritical fluids 
 
12 
 
1.3.1.  Applications .................................................................................. 52 
1.3.2.  Types of extrusion......................................................................... 53 
1.3.2.1. Wet extrusion .......................................................................... 53 
1.3.2.2. Solvent-free extrusion and solid lipid extrusion ........................ 53 
1.3.2.3. Hot-melt extrusion ................................................................... 54 
1.3.2.4. Cold extrusion ......................................................................... 54 
1.3.2.5. Discontinuous extrusion .......................................................... 55 
1.3.2.6. Continuous extrusion ............................................................... 55 
1.3.3.  Extruders ...................................................................................... 55 
1.3.4.  Shapes of extrudates .................................................................... 56 
1.3.5. Materials for extrusion ............................................................. 56 
1.3.5.1. Materials for extrusion at room temperature, in the 
absence of solvents ................................................................................ 58 
1.3.5.2. Formulations for extrusion ....................................................... 58 
1.3.6.  Process of extrusion and co-extrusion .......................................... 59 
1.3.6.1. Operational parameters and equipment features ..................... 59 
1.3.6.2. Characterizing the extrusion process (extrusion profiles) ......... 60 
1.3.6.3. Other manufacturing operations involved ................................ 61 
1.3.7.  Characterization and properties of extrudates and co-extrudates .. 62 
1.3.7.1. Surface .................................................................................... 62 
1.3.7.2. Thickness ................................................................................ 63 
1.3.7.3. Density and porosity ................................................................ 63 
1.3.7.4. Mechanical properties ............................................................. 63 
1.3.7.5. Thermal behavior .................................................................... 64 
1.3.8.  Further processing of extrudates ................................................... 64 
1.4.  Model drugs ....................................................................................... 66 
1.4.1.  Coumarin ...................................................................................... 66 
Production of laminar extrudates containing particles of a model drug processed by supercritical fluids 
 
13 
 
1.4.2.  Levothyroxine (free acid) .............................................................. 66 
CHAPTER 2.................................................................................................... 67 
Characterization of coumarin particles micronized by the rapid 
expansion of supercritical solutions (RESS) technique ............................ 67 
2.1.  Introduction ........................................................................................ 69 
2.2.  Aim of study ....................................................................................... 70 
2.3.  Materials and methods ....................................................................... 70 
2.3.1.  Materials ....................................................................................... 70 
2.3.2.  Methods ........................................................................................ 71 
2.3.2.1. Manufacture of coumarin particles ........................................... 71 
2.3.2.2. Characterization of particles .................................................... 72 
2.3.2.3. Analysis of data ....................................................................... 75 
2.4. Results ................................................................................................ 75 
2.4.1. Properties of coumarin particles ..................................................... 75 
2.4.2. RESS experimental conditions ....................................................... 80 
2.5.  Discussion.......................................................................................... 83 
2.6.  Conclusions ....................................................................................... 86 
CHAPTER 3.................................................................................................... 87 
Characterization of laminar extrudates manufactured at room 
temperature in the absence of solvents ..................................................... 87 
3.1.  Introduction ........................................................................................ 89 
3.2  Aim of study ....................................................................................... 90 
3.3.  Materials and methods ....................................................................... 90 
3.3.1.  Materials ....................................................................................... 90 
3.3.2.  Methods ........................................................................................ 91 
Production of laminar extrudates containing particles of a model drug processed by supercritical fluids 
 
14 
 
3.3.2.1. Preparation of extrudates ........................................................ 91 
3.3.2.2. Characterization of extrudates ................................................. 94 
3.3.2.2.1. Physical characterization .................................................. 94 
3.4.  Results and discussion....................................................................... 95 
3.4.1.  Manufacture of extrudates ............................................................ 95 
3.4.2.  Visual inspection of extrudates ................................................... 100 
3.4.3.  Thickness of extrudates .............................................................. 102 
3.4.4.  Density and porosity of extrudates .............................................. 102 
3.4.5.  Thermal behavior of raw materials and of extrudates over time .. 105 
3.4.7.  Release of coumarin from extrudates ......................................... 113 
3.5.  Conclusions ..................................................................................... 116 
CHAPTER 4.................................................................................................. 119 
Delivery of drugs from laminar co-extrudates manufactured by a 
solvent-free process at room temperature ............................................... 119 
4.1.  Introduction ...................................................................................... 121 
4.2.  Aim of study ..................................................................................... 122 
4.3.  Materials and methods ..................................................................... 122 
4.3.1.  Materials ..................................................................................... 122 
4.3.2.  Methods ...................................................................................... 123 
4.3.2.1. Manufacture of extrudates and co-extrudates ........................ 123 
4.3.2.2. Characterization of extrudates ............................................... 125 
4.3.2.2.1. Extrusion profiles and force at steady state (FSS) ............ 125 
4.3.2.2.2. Morphological evaluation ................................................ 125 
4.3.2.2.3. Thickness of extrudates .................................................. 126 
4.3.2.2.4. Density and porosity of extrudates .................................. 126 
4.3.2.2.5. Mechanical characterization of extrudates ...................... 126 
Production of laminar extrudates containing particles of a model drug processed by supercritical fluids 
 
15 
 
4.3.2.2.6. Thermal behavior of extrudates....................................... 126 
4.3.2.2.7. Release of coumarin from extrudates.............................. 127 
4.4.  Results ............................................................................................. 127 
4.4.1.  Extrusion profiles and force at steady state (FSS) ........................ 127 
4.4.2.  Morphological evaluation of extrudates ....................................... 128 
4.4.3.  Physical characterization of extrudates ....................................... 130 
4.4.3.1. Thickness .............................................................................. 130 
4.4.3.2. Density and porosity .............................................................. 130 
4.4.3.3. Mechanical characterization .................................................. 132 
4.4.3.4. Thermal behavior .................................................................. 135 
4.4.3.5. Release of coumarin ............................................................. 139 
4.5.  Discussion........................................................................................ 141 
4.6.  Conclusions ..................................................................................... 147 
CHAPTER 5.................................................................................................. 149 
Release of coumarin from laminar extrudates containing coumarin 
particles manufactured by RESS ............................................................... 149 
5.1.  Introduction ...................................................................................... 151 
5.2.  Aim of study ..................................................................................... 151 
5.3.  Materials and methods ..................................................................... 151 
5.3.1.  Materials ..................................................................................... 151 
5.3.2.  Methods ...................................................................................... 152 
5.3.2.1. Preparation of laminar extrudates with coumarin ................... 152 
5.3.2.2. Characterization of materials and products............................ 153 
5.4.  Results ............................................................................................. 155 
5.4.1.  Manufacture of extrudates .......................................................... 155 
5.4.2.  Visual inspection of extrudates ................................................... 155 
Production of laminar extrudates containing particles of a model drug processed by supercritical fluids 
 
16 
 
5.4.3.  Thickness of extrudates .............................................................. 157 
5.4.4.  Density, porosity and mechanical properties of extrudates .......... 157 
5.4.5.  Thermal behavior of raw materials and of extrudates over time .. 157 
5.4.6.  Release of coumarin from extrudates ......................................... 164 
5.5.  Discussion........................................................................................ 165 
5.6.  Conclusions ..................................................................................... 167 
CHAPTER 6.................................................................................................. 169 
Oral and transdermal delivery of drugs from laminar extrudates 
manufactured at room temperature and in the absence of solvents: 
an in-vitro study in excised skin and an in-vivo study in rats ................ 169 
6.1.  Introduction ...................................................................................... 171 
6.2.  Aim of study ..................................................................................... 172 
6.3.  Materials and methods ..................................................................... 172 
6.3.1.  Materials ..................................................................................... 172 
6.3.2.  Methods ...................................................................................... 172 
6.3.2.1. Manufacture of laminar extrudates ........................................ 172 
6.3.2.2. Characterization of laminar extrudates .................................. 173 
6.3.2.3. In-vitro permeation of coumarin and levothyroxine through 
excised skin .......................................................................................... 174 
6.3.2.4. In-vivo delivery of levothyroxine ............................................. 176 
6.4.  Results and discussion..................................................................... 178 
6.4.1.  Manufacture of laminar extrudates .............................................. 178 
6.4.2.  Characterization of laminar extrudates ........................................ 178 
6.4.3.  In-vitro permeation of coumarin and levothyroxine through 
excised skin ............................................................................................. 179 
6.5.  Conclusions ..................................................................................... 182 
Production of laminar extrudates containing particles of a model drug processed by supercritical fluids 
 
17 
 
CHAPTER 7.................................................................................................. 183 
Overall conclusions .................................................................................... 183 
7.1.  Summary of findings ........................................................................ 185 
7.2.  Achievements .................................................................................. 185 
7.3.  Verification of the hypothesis in study .............................................. 186 
7.4.  Added value ..................................................................................... 186 
FUTURE PERSPECTIVES ........................................................................... 189 
REFERENCES ............................................................................................. 193 
 
 
 
 
 
 
  
 
 
 
 
Production of laminar extrudates containing particles of a model drug processed by supercritical fluids 
19 
 
Abstract 
The aim of this work was to test the hypothesis that laminar extrudates and 
co-extrudates, containing particles of drugs processed by supercritical fluids, can be 
manufactured at room temperature and in the absence of solvents, to deliver drugs 
by the oral or transdermal routes of administration. 
Particles of coumarin (drug) were manufactured by Rapid Expansion of 
Supercritical Solutions (RESS), which is a supercritical fluid micronization technique, 
using both a discontinuous and a continuous mode of operation. The manufactured 
particles of coumarin obtained from different RESS experiments, in which there were 
tested different experimental conditions, presented reduced sizes (between 20-40 
µm, mean values) and similar properties in terms of morphology, surface area, 
thermal behavior, amorphous and crystalline contents, density and porosity. 
It was observed that specific experimental conditions of the RESS influenced 
the size of the manufactured drug particles, namely the pre-expansion pressure, the 
initial amount of solute, and the post-expansion pressure, amongst others. 
In parallell, several excipients and different formulations were developed and 
tested in order to manufacture extrudates with a laminar shape, at room temperature, 
and without including solvents in the formulations. The lipid-based materials were the 
excipients that better contributed for the aim of the study, as the formulations with 
these excipients in high proportions presented suitable physical and mechanical 
properties and, in consequence, a satisfactory quality. 
After identifying the best formulation, the extrusion processing parameters 
and their influence in the properties of the manufactured extrudates, namely the 
extrusion rate, were properly studied. Additionally, for each extrudate, there were 
analyzed the dissolution profiles, the thermal behaviors of the raw materials before 
extruding and of the extrudates after extrusion and over the storage period, as well 
as the evolution of the density, of the porosity and of the mechanical properties of the 
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extrudates such as the bending strength, the deformation, the stiffness, and the 
elasticity (Young’s modulus). 
It was studied the release of the drug from extrudates containing particles of 
drugs with different sizes in order to assess the impact of the particle size of the drug 
on its release from the extrudates previously manufactured. It was concluded that the 
manufacture of extrudates at room temperature and without including solvents in the 
formulation is a promising technology for the manufacture of new pharmaceutical 
dosage forms. All the analysis performed both to the starting materials and to the 
obtained extrudates showed that after extrusion occurs an aging phenomenon of the 
extrudates, which is visible by the evident changes in their physical and mechanical 
properties over storage. This phenomenon is similar to the previously observed and 
described for the glycerides and triglycerides that mainly compose the lipid-based 
excipients selected for this study. 
The formulations composed by different excipients originated extrudates with 
different properties such as the mechanical properties. Also, the bending strength, 
the stiffness, the deformation, the elasticity, the density and the porosity changed 
over time, and the observed changes were related to the composition of the 
formulations and of the extrusion processing conditions. 
It was observed that the properties of the extrudates, namely their physical 
and mechanical properties, needed to be stabilized over time in order to maintain 
unaffected the release of the drug performance expected for certain drug and 
extrudate. Additionally, the extrudates including particles of drugs with smaller sizes 
presented higher release rates when compared with particles with higher dimensions. 
The formulations and the components selected for the manufacture of 
extrudates at room temperature and in the absence of solvents were in the majority 
composed by lipid-based materials, which can sustain the release of the drug. 
Therefore, it was concluded that the release rate of a certain drug can be modified by 
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changing the composition of the formulatons and/or by changing the size of the 
particles of drug. 
The entire approach for the formulation development and for the study of the 
extrusion process and of the properties of the extrudates was replicated for the 
development of the laminar co-extrudates (with two or three layers). The properties 
and results obtained were similar to those observed for the extrudates with a single 
layer. 
The particles of coumarin micronized by RESS were included in laminar 
extrudates manufactured without changing the temperature during processing and 
avoiding the inclusion of solvents in the formulation. The release of coumarin from 
these extrudates was assessed and it was concluded that this pharmaceutical 
dosage form could successfully transport and release coumarin. 
Those laminar extrudates were also tested for its ability in delivering coumarin 
obtained by RESS and levothyroxine by both the oral and the transdermal routes of 
administration. The particles of both drugs, in separate, were included in formulations 
of extrudates and its in-vitro release, ex-vivo permeation and in-vivo absorption / 
permeation were properly assessed. 
Several portions of extrudates containing coumarin or levothyroxine were 
placed in the donor compartments of diffusion cells (Franz cells) containing a barrier 
composed by human skin (ex-vivo experiment) and it was observed that both drugs 
were successfully released and permeated through the skin. Also, several portions of 
extrudates containing levothyroxine were delivered to Wistar rats by both routes of 
administration (oral and transdermal) and it was observed that levothyroxine was 
respectively absorbed and permeated, being detected in the blood mainstream of the 
mice. 
All the findings described in this work allowed to conclude that the hypothesis 
was valid and that it is possible to manufacture extrudates and co-extrudates at room 
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temperature, without including solvents containing particles of a drug manufactured 
by supercritical fluids. 
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Resumo 
O trabalho desenvolvido no âmbito desta Tese pretendeu testar a hipótese 
de que extrudidos e co-extrudidos laminares contendo partículas de fármacos 
micronizadas por uma técnica de fluidos supercríticos, podem ser produzidos à 
temperatura ambiente e sem a inclusão de solventes, permitindo a veiculação de 
fármacos pelas vias de administração oral e transdérmica. 
A produção de partículas de cumarina (fármaco) por intermédio de uma 
técnica de micronização por fluidos supercríticos – Rapid Expansion of Supercritical 
Solutions (RESS) – foi testada segundo duas modalidades de operação distintas: 
operação descontínua e operação contínua. 
Nas experiências de RESS em modo descontínuo, uma porção de cumarina 
(soluto) foi colocada na câmara de extração e o dióxido de carbono (solvente) foi 
injetado até obtidas determinadas pressão (15-42 MPa) e temperatura (40-60 ºC) 
atingindo o estado supercrítico. Todo o soluto foi dissolvido no dióxido de carbono 
supercrítico, formando-se uma solução supercrítica de cumarina. De seguida, a 
solução supercrítica foi transferida para a câmara de expansão que se encontrava a 
pressão e temperatura atmosféricas. Esta mudança abrupta das condições de 
pressão e temperatura levou à transformação do dióxido de carbono supercrítico em 
gás e provocou a super-saturação da solução supercrítica com a consequente 
precipitação da cumarina em partículas. Toda esta mudança brusca de condições 
(temperatura e pressão) levou ao crescimento extremamente rápido de núcleos de 
cristalização, dando origem a partículas muito finas e com diâmetros com cerca de 
30 a 50 µm (valores médios).  
De forma a extrair a maior quantidade possível de cumarina, o decréscimo de 
pressão verificado na câmara de extração aquando da transferência da solução 
supercrítica para a câmara de expansão, foi compensado pela injeção de novas 
quantidades de dióxido de carbono na câmara de extração, reestabelecendo-se 
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assim as condições iniciais de pressão e completando-se um ciclo de expansão. 
Vários ciclos foram realizados de forma a melhorar o rendimento do processo. 
No caso das experiências RESS em modo contínuo, foi estabelecida a 
circulação contínua da solução supercrítica de cumarina entre as câmaras de 
extração e de expansão, através da injeção contínua e constante de dióxido de 
carbono na câmara de extração. Desta forma, toda a cumarina foi extraída e 
transferida para a câmara de expansão sem qualquer paragem do processo e sem a 
necessidade de injeção de porções de dióxido de carbono para restabelecimento da 
pressão interna na câmara de extração. O processo decorreu de forma contínua. 
Em ambas as modalidades de operação da tecnologia RESS, verificou-se a 
formação de partículas de cumarina com dimensões reduzidas (20-40 µm, valores 
médios). No entanto, também se verificou que as várias condições de processo 
selecionadas podem influenciar as propriedades das partículas obtidas por RESS, 
nomeadamente: o aumento da temperatura de pré-expansão e da pressão de pré-
expansão, dão origem ao aumento do tamanho médio das partículas obtidas. Ao 
contrário, verificou-se que a diminuição da temperatura de expansão e da pressão 
de expansão, levam à diminuição do tamanho médio das partículas obtidas, pelo 
que o controlo das condições de processamento é bastante crítico para a obtenção 
de partículas com propriedades específicas. 
Para além do estudo do tamanho da partícula e da distribuição dos tamanhos 
de partícula, também foram estudadas outras propriedades das partículas de 
cumarina – como a área de superfície, a densidade, o conteúdo amorfo / cristalino e 
o comportamento térmico – e a influência das condições de processo da tecnologia 
RESS nessas propriedades, concluindo-se que ambas as modalidades de operação 
(descontínua e contínua) e que as várias alterações testadas às condições de 
processo, dão origem a partículas com propriedades equivalentes. 
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Em paralelo, e de forma produzir extrudidos laminares sem a inclusão de 
solventes nas formulações e sem alteração das condições de temperatura ambiente 
durante o processo, foram desenvolvidas e testadas várias formulações. Foram 
experimentados igualmente vários excipientes e verificou-se que os excipientes 
lipídicos sólidos são os materiais mais promissores, na medida em que as 
formulações que os continham em maior proporção produziram os extrudidos com 
melhor qualidade. De igual forma, várias combinações e proporções de excipientes 
foram ensaiadas até serem definidas as formulações mais adequadas. 
Numa primeira fase, e depois de selecionada uma formulação base, foram 
estudados os parâmetros de processo e a sua influência nas propriedades dos 
extrudidos produzidos, nomeadamente a velocidade de extrusão utilizada. Para cada 
extrudido foram analisados os perfis de extrusão, o comportamento térmico dos 
excipientes antes da extrusão e o comportamento térmico dos extrudidos após a 
extrusão ao longo do tempo (período de armazenamento), assim como a evolução 
da densidade, da porosidade e das suas propriedades mecânicas, nomeadamente a 
resistência à flexão, a deformação, a rigidez e a elasticidade (módulo de Young), 
após a extrusão e durante o armazenamento. 
Foi igualmente estudada a libertação do fármaco a partir de extrudidos 
contendo partículas de fármaco com diferentes tamanhos e diferentes distribuições 
de tamanho de partícula, de forma a avaliar o impacto do tamanho da partícula do 
fármaco na sua libertação a partir dos extrudidos anteriormente produzidos. 
Concluiu-se que a produção de extrudidos laminares à temperatura ambiente 
e sem a inclusão de solventes na formulação é uma tecnologia promissora para o 
fabrico de novas formas farmacêuticas. Toda a análise efetuada aos materiais e aos 
extrudidos obtidos permitiu verificar que após extrusão ocorre um processo de 
envelhecimento dos extrudidos que se manifestou pela alteração das suas 
propriedades físicas e mecânicas ao longo do tempo. Este fenómeno foi semelhante 
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ao previamente observado e descrito para os glicerídeos e para os triglicerídeos, 
que compõem grande parte dos excipientes lipídicos utilizados nas formulações. 
Observou-se igualmente que formulações compostas por diferentes excipientes ou 
por diferentes proporções dos mesmos excipientes originaram extrudidos com 
propriedades diferentes, nomeadamente as propriedades mecânicas. A resistência à 
flexão, a rigidez, a deformação, a elasticidade, a densidade e a porosidade dos 
extrudidos alterou-se ao longo do tempo, sendo que esta alteração é dependente da 
composição e das condições de processo durante a extrusão. 
Concluiu-se que as propriedades dos extrudidos, nomeadamente as 
propriedades físicas e mecânicas, necessitam de ser estabilizadas ao longo do 
tempo de forma a que estas alterações não afetem a performance de libertação do 
fármaco esperada para determinados extrudidos. 
Verificou-se ainda que os extrudidos incluindo partículas de fármaco com 
diferentes tamanhos apresentaram perfis de libertação diferentes. Os extrudidos 
com as partículas de cumarina mais pequenas apresentaram taxas de libertação do 
fármaco mais elevadas quando comparadas com partículas de maiores dimensões. 
Estes extrudidos laminares, ao serem compostos maioritariamente por 
excipientes lipídicos, apresentaram uma libertação retardada do fármaco. Dessa 
forma, pode-se concluir que as taxas de libertação do fármaco podem ser 
modificadas através da alteração da composição da formulação e/ou alterando o 
tamanho das partículas de fármaco incluídas. 
Toda a abordagem de desenvolvimento das formulações, do estudo do 
processo de extrusão e do estudo das propriedades dos extrudidos foi replicada 
para o desenvolvimento de co-extrudidos laminares, contendo duas ou três camadas 
justapostas. Os resultados obtidos foram similares aos verificados para os 
extrudidos de uma única camada. 
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As partículas de cumarina obtidas pela tecnologia de RESS foram 
posteriormente incluídas em extrudidos laminares produzidos sem a inclusão de 
qualquer solvente e sem aquecimento do extrusor durante o processo. A libertação 
da cumarina a partir destes extrudidos foi avaliada e concluiu-se que esta forma 
farmacêutica permitiu o transporte e libertação destas partículas de cumarina. 
Os extrudidos laminares foram testados quanto à sua capacidade de 
veiculação e administração pelas vias de administração oral e transdérmica de 
partículas de cumarina obtidas pelo método de RESS e de partículas de levotiroxina. 
As partículas de ambos os fármacos, em separado, foram incluídas em 
formulações de extrudidos semelhantes às descritas anteriormente e os extrudidos 
laminares obtidos e a sua libertação in-vitro, permeação ex-vivo e absorção / 
permeação in-vivo foram avaliadas e estudadas. 
Várias porções de extrudidos contendo cumarina e de extrudidos contendo 
levotiroxina foram colocados em compartimentos dadores de células de difusão 
(células de Franz) de forma a confirmar a capacidade destes extrudidos em libertar 
os fármacos e de estes permearem uma barreira constituída por pele humana 
(estudo ex-vivo). Verificou-se que ambos os fármacos foram libertados pelos 
extrudidos e atravessaram a pele com sucesso. 
De igual modo, as várias porções de extrudidos contendo levotiroxina 
administradas a ratos Wistar (macho) pelas vias de administração oral e 
transdérmica, libertaram o fármaco e este foi permeado e absorvido com sucesso, 
sendo detectado no sangue dos ratinhos. 
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1.  Challenges 
The pharmaceutical development and the manufacture of medicinal 
products comprise important challenges that must be appropriately addressed. In the 
majority of the cases, these challenges represent severe obstacles to the delivery of 
drugs and, in consequence, limit the therapeutic options available. Therefore, it is 
crucial to find strategies for overcoming these limitations, widening the 
pharmaceutical alternatives for delivering drugs and contribute to the lifecycle 
management of medicines. 
The processing of thermo-sensitive and/or solvent-sensitive drugs is 
an example of the referred limitations. Also, the poor bioavailability of drugs, resulting 
of a non-complete absorption or permeation, can impair the desired therapeutic 
goals. 
Additionally, the need for delivering more than one drug in the same 
dosage form, the benefit from delivering a drug with two different release profiles 
within the same dosage form, and the need to provide adequate and specific doses 
to special groups of patients that do not have an appropriate dosage available in the 
market (e.g. pediatrics), represent strong limitations to the delivery of drugs and 
require mitigations by pharmaceutical scientists. 
From a different perspective, the existing pressure for reducing 
manufacturing costs and to meet ecological demands represents daily challenges for 
pharmaceutical scientists. 
 
2.  Motivation and aim 
The motivation for this study was to explore the potential of two 
specific technologies – supercritical fluids and extrusion – for addressing some of the 
referred drug delivery obstacles and overcoming the identified barriers, providing new 
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proposals for the problems and representing a step forward in the development of 
new pharmaceutical dosage forms. 
The aim of this thesis is to challenge both technologies and to identify 
the best strategies for using and testing up most of the advantages of the selected 
technologies and to develop the best methodologies for obtaining pharmaceutical 
dosage forms that will deliver drugs to patients in ideal conditions. More specifically, 
to explore new experimental conditions for manufacturing drug particles with reduced 
sizes by a supercritical fluids technology, and to develop new formulations for 
extrusion allowing the preservation of the properties of the drug particles previously 
manufactured, together with new ways of performing the extrusion process. 
 
3.  Hypothesis 
 
Laminar extrudates and co-extrudates, containing particles of 
drugs processed by supercritical fluids, can be manufactured at room 
temperature and in the absence of solvents, to deliver drugs by the oral or 
transdermal routes of administration. 
 
4.  Research objectives and outcomes 
The main purpose of this work was to use two existing technologies – 
supercritical fluids and extrusion – to build up alternatives for overcoming the 
pharmaceutical challenges described previously. 
 
The research objectives pursued were: 
- to manufacture and characterize particles of model drugs with 
reduced sizes by a supercritical fluid technology – Rapid 
Expansion of Supercritical Solutions (RESS); 
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- to manufacture and characterize extrudates and co-extrudates 
with a laminar shape in the absence of solvents minimizing 
changes of temperature during processing (green technologies); 
- to deliver the manufactured drug particles with reduced sizes 
within the laminar extrudates and co-extrudates prepared. 
 
The expected research outputs were: 
- particles of a model drug with reduced size (micro and nanometer 
scale)  engineered by RESS; 
- laminar extrudates and co-extrudates containing at least a layer 
with particles of the model drug manufactured by RESS. 
 
5.  Organization of the thesis 
The thesis comprises several chapters that describe the technologies 
selected and products available for the study (Chapter 1) and summarize all the 
laboratorial work and research findings (Chapters 2 – 6), more specifically: 
- the manufacture and characterization of particles with reduced 
size by the Rapid Expansion of Supercritical Solutions (RESS) 
technology (bottom-up approach) by comparison with the 
conventional milling (top-down approach) (chapter 2): 
- the manufacture and characterization of laminar extrudates at 
room temperature and in the absence of solvents, focusing on the 
description and assessment of the innovative extrusion process 
(chapter 3); 
- the manufacture and characterization of innovative laminar co-
extrudates at room temperature and in the absence of solvents 
(chapter 4); 
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- the in-vitro assessment of the release of drugs from laminar 
extrudates and co-extrudates containing particles of drugs 
manufactured by supercritical fluids (chapter 5); 
- the study of the in-vivo delivery of model drugs by oral and 
transdermal routes of administration from laminar extrudates 
(proof-of-concept) (chapter 6); 
Chapter 7 summarizes the findings together with the overall 
conclusions drawn, demonstrating the hypothesis raised in the beginning of this 
work. 
The last section, ‘future perspectives’ raises some questions, which 
were not answered in this work, and new questions beyond the scope of this work 
enabling the reader to get a better view of this research area. 
It must be referred that some chapters were adapted from articles 
published in peer-reviewed journals and, therefore, follow the original structure of 
those journals. 
 
 
  
 
 
 
 
 
 
 
 
CHAPTER 1 
 
 
 
Introduction 
 
  
  
 
 
 
 
Production of laminar extrudates containing particles of a model drug processed by supercritical fluids 
 
47 
 
1.1.  Reduction of the size of particles 
The size of drug particles can be reduced by decreasing the size of 
the original materials (top-down approach) or by increasing the size from solutions 
(bottom-up approach). Classically, the reduction of the particle size achieved by 
mechanical comminution considering techniques such as milling exemplify the top-
down approach, whereas spray-drying, freeze-drying, precipitation or crystallization 
from solutions are alternative techniques representing the bottom-up approach. 
However, these micronizing technologies present disadvantages that 
limit their use, such as the production of coarse particles or broad particle size 
distributions (1), the contamination of the particles with solvent residues or other 
impurities, the use of large amounts of solvents (that create environmental problems 
related to the solvent disposal), and/or the degradation of the substances due to 
thermal, chemical or mechanical stresses (2). To minimize these limitations, 
alternative technologies have been developed in recent years, namely the application 
of supercritical fluid (SCF) technologies in designing particles of drugs (3). 
 
1.1.1.  Top-down approaches 
In the micronization of solid drug particles by mechanical comminution 
(e.g. milling, crushing, grinding) to obtain particles with smaller sizes, the reduction of 
size occurs by at least one of the following mechanisms: pressure, friction, attrition, 
impact, or shearing. Generally, more than one of these mechanisms is observed 
simultaneously. There is no nucleation for creating a new particle but only the 
alteration of the existing particles. It is important to refer that all other properties than 
size of the obtained particles also result directly from these mechanical phenomena, 
namely the amorphous / crystalline content, the density and porosity, amongst others 
(4). 
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1.1.2.  Bottom-up approaches 
In all bottom-up approaches for designing particles of drugs with 
reduced sizes, there is a complete solubilization of the solute / drug being processed 
in the solvent(s). Afterwards, taking into consideration specific methodologies related 
to each technology, the solution is transformed into solid particles with reduced sizes 
by eliminating the solvent(s) and further precipitating the solute, which acquires its 
solid-state properties. In general, the speed of both the elimination of the solvent(s) 
and the change of the solute to the solid-state, influences the size of the obtained 
particles (5). 
Techniques such as the spray-drying (6), the freeze-drying (7) or the 
supercritical fluids (8), are examples of technologies applied in the reduction of the 
size of the particles of drugs with bottom-up approaches. 
 
1.1.2.1. Supercritical fluids techniques 
Several technologies based on the use of supercritical fluids for 
obtaining particles with reduced sizes have been developed in recent years. The 
supercritical anti-solvent (SAS), the supercritical-assisted atomization (SAA), the gas 
anti-solvent (GAS), the aerosol solvent extraction system (ASES), particles from gas-
saturated solutions (PGSS), and the rapid expansion of supercritical solutions 
(RESS), amongst others, are examples of those technologies (9). 
The RESS technique has been more attractive than the others as the 
obtained particles are free of residual solvents, the size of the particles can be 
controlled and adjusted, and the operating conditions in terms of temperature and 
pressure are considered mild. Therefore, the RESS method has been widely applied 
in the micronization of particles of drugs (10). 
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1.2.  Rapid expansion of supercritical solutions (RESS) 
The rapid expansion of a solution in the supercritical state has been 
used for designing small, uniform and solvent-free particles or powders, as it can 
produce fine particles of a wide range of inorganic, organic and polymeric materials 
(11). Drugs such carbamazepine, ibuprofen, paclitaxel, and nabumetone, amongst 
others, have been micronized by RESS (1, 12-14). 
The RESS methodology promotes the bioavailability of drugs (15, 16) 
by creating particles with narrow size distributions and increased surface area (17), 
and is simultaneously considered a mild and green technology as it does not produce 
residual solvents or in case solvents / gases are used, they can be recycled and re-
utilized (2). This RESS methodology has specific features that need to be adequately 
explored in order to extract the highest potential of this technique. 
In the case of the supercritical solvent processes such as the rapid 
expansion of supercritical solutions (RESS), the solute is directly dissolved in the 
supercritical phase forming a supercritical solution, which is expanded by passing 
through a nozzle. This expansion, caused by a rapid decrease of the pressure and 
temperature of the supercritical solution, leads to an abrupt decrease of the solute’s 
solubility. In consequence, the existing equilibrium between the solute and the 
solvent ends, leading to the formation of very fines particles of solute by precipitation 
(18). 
 
1.2.1.  Concept 
The RESS technique uses the solvating power of fluids in the 
supercritical state for dissolving solid materials that cannot be dissolved at 
atmospheric conditions of pressure and/or temperature. 
The particles manufactured by RESS are very fine (from nanometer to 
micrometer sized particles) and present very narrow size distributions due to the very 
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fast crystallization of the dissolved solute. After the dissolution of the solute in the 
supercritical fluid, occurs a very fast change of the supercritical fluid to the gas-like 
properties: the expansion. This abrupt change originates a high super-saturation and, 
consequently, the particle formation (19). Experimental conditions such as the 
extraction pressure, the extraction temperature, the initial concentration of the solute, 
and the configuration of the noozle, amongst others, have an influence in the final 
properties of the manufactured particles with this technique (20). 
 
1.2.2.  Solvents used in RESS 
The solvents used in RESS as supercritical fluids are gases 
pressurized and heated above their critical point (higher pressure and temperature), 
exhibiting simultaneously gas-like and liquid-like properties. Therefore, these fluids in 
supercritical state exhibit densities close to liquids and viscosities close to gases or 
vapors (11). 
Carbon dioxide (CO2), trifluoromethane (CHF3) and propane (C3H8) 
are gases commonly used in the dissolution / extraction of materials (21). The carbon 
dioxide is the most commonly used fluid as it is inexpensive and easily recyclable. 
Additionally, CO2 presents a relatively low critic temperature and a moderate critic 
pressure, leaves no residues and is not flammable. 
 
1.2.3.  Particle formation 
The particles are formed during the expansion of the solution, in which 
there is a fast nucleation. When the supercritical solution is transferred between the 
extraction and the expansion chambers, there is an abrupt change of pressure, 
together with a change of temperature, to the atmospheric conditions. There is an 
immediate removal of the solvent, which changes from the liquid to the gaseous 
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state, leading to a high super-saturation and an immediate transformation of the 
solubilized drug to the solid state through nucleation (22, 23). 
 
1.2.4.  Process parameters influencing the properties of the particles 
Various process parameters have influence in the final properties of 
the particles manufactured by RESS, such as the extraction temperature, the 
extraction pressure, the pre-expansion temperature, the spray distance, post-
expansion pressure, and the nozzle configuration (length, diameter and geometry) (3, 
9, 13, 14, 24-26). 
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1.3.  Extrusion and co-extrusion 
Extrusion is defined as the process of forming a new product 
(designated as the extrudate) with uniform shape and density, by forcing a material 
or a mixture of materials, under controlled conditions, through a die or orifice. The 
new product acquires the shape of the extrusion die. Co-extrusion consists on the 
simultaneous extrusion of two or more materials (or mixtures of materials) in order to 
create a multi-layered extrudate (27). 
 
1.3.1.  Applications 
The extrusion and co-extrusion techniques have been widely applied 
in various industries such as the food, ceramics, plastics, metals, and electronics 
industries (28-38), but also in biomedical, nutraceutical and pharmaceutical 
applications (39-41). 
In the pharmaceutical field, the wet and hot-melt extrusion processes 
are commonly applied in the manufacture of drug products. However, these 
processes present some limitations, namely the use of solvents in the formulations 
(e.g. water) and/or changes on temperature during manufacturing (hot melt). Due to 
these limitations, certain drugs cannot be processed by extrusion, as they are solvent 
and/or heat sensitive. Thus, the possibility of performing extrusion without the use of 
solvents and changes in temperature during processing represents a step forward in 
the field, allowing a wider application and turning this technology into a green 
process (42). 
Various pharmaceutical dosage forms have been manufactured 
through the extrusion or co-extrusion processes, namely pellets (43), granules (44), 
tablets (45, 46), transdermal or transmucosal films (47), implants (48), and 
periodontal inserts (49). 
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These dosage forms are suitable for administration via different routes, 
which vary from the oral, transdermal, transmucosal, and transungual routes of 
administration (48). 
 
1.3.2.  Types of extrusion 
There are several types of extrusion and co-extrusion – wet or paste, 
dry or solvent-free, hot-melt or melt, cold, and solid lipid extrusion – depending on the 
inclusion of solvents, on the temperature changes during processing and on the 
materials that are used (50). Additionally, the processes of extrusion can be 
categorized according to the operation mode: discontinuous (e.g. ram extrusion) or 
continuous (e.g. screw extrusion) processes. 
 
1.3.2.1. Wet extrusion 
The wet extrusion or co-extrusion, also known as paste extrusion, 
requires the formation of a homogeneous mixture of powdered materials (dry mixing), 
which is wet massed with the addition of a liquid binder (e.g. water). Afterwards, the 
moistened / wet mass is pressed through a die to form the extrudates, which can be 
further processed. Wet extrusion is widely applied in the pharmaceutical field 
especially in the manufacture of pellets (51). 
 
1.3.2.2. Solvent-free extrusion and solid lipid extrusion 
The formulations for solvent-free extrusion or co-extrusion, also 
designated as dry extrusion, do not include any liquid excipients or solvents as 
extrusion aids. In general, the solvent-free extrusion is a two-step process starting 
with the blending of solid materials, which afterwards are directly fed into the extruder 
chambers for processing. Solvent-free extrusion is advantageous when delivering 
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drugs sensitive to moisture or solvents, reducing the possibility of occurring 
degradation of the drug and further change of properties (42). 
The solid lipid extrusion or co-extrusion is a kind of solvent-free 
extrusion, in which powdered lipids are mixed with drugs and extruded at a 
temperature below the melting ranges of the lipids. Therefore, the lipids do not melt 
but only soften, and the drug is dispersed in it (42, 52). 
 
1.3.2.3. Hot-melt extrusion 
In hot-melt extrusion or co-extrusion, also known as melt extrusion, a 
powder blend of drug(s) and carrier(s) is heated, melted and pressed through the die. 
Neither water nor solvents are used. Therefore, degradation of the drugs due to 
hydrolysis is avoided. When the intention is to deliver thermo-sensitive drugs, the use 
of the hot-melt extrusion process needs to be appropriately evaluated in order to 
prevent any degradation or loss of properties due to the effect of temperature 
increase (53). 
Different dosage forms have been manufactured via hot-melt 
extrusion, such as pellets, granules, tablets, implants, suppositories, films, amongst 
others (54). Nowadays, the hot-melt extrusion technique has been especially used 
for increasing the solubility of polymers. 
 
1.3.2.4. Cold extrusion 
In cold extrusion or co-extrusion there are no changes of temperature 
during processing, which is advantageous when delivering drugs that are thermo-
sensitive. After an appropriate mixture of the excipients and drugs, the extrudable 
mass is fed into the extruder chamber for further extrusion at room temperature (42). 
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1.3.2.5. Discontinuous extrusion 
Discontinuous extrusion or co-extrusion, in which are mainly used ram 
or piston extruders, is generally used for laboratory purposes or for extruding 
specialized materials that require a strict control. In ram extrusion, the displacement 
of the ram generates high pressures, forcing the extrudable masses to cross the 
dies. The materials are feed to a barrel (which is heated in the majority of the cases) 
and forced through the die being transformed into a solid product with a specific and 
desired shape. The feeding of the materials and extrusion of masses is not 
continuous (55). 
 
1.3.2.6. Continuous extrusion 
Continuous extrusion or co-extrusion, in which are mainly used screw 
extruders, is used for industrial purposes. These extruders present one, two or 
multiple rotating screws, which continuously push the extrudable masses inside a 
heated barrel towards an extrusion screen. The screw extrusion presents a high 
throughput rate, allows an easy cleaning and the usage of different screen types 
(56). 
 
1.3.3.  Extruders 
In general, all types of extruders – the ones classified as screw-, 
gravity- and piston-type extruders, and also the ones classified as sieve and basket, 
roll, and ram extruders – include a part for transporting and feeding the extrudable 
masses into the extrusion chambers, and a screen or die through which the materials 
are pushed, shaping the extrudates (57). 
The ram extruders include the following components: a stainless steel 
barrel, consisting of a reservoir for the extrudable materials; different dies with 
different shapes and/or dimensions, which are installed in the base of the barrel; and 
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a stainless steel piston, or ram, that fits loosely into the barrel. The ram extruders 
allow the non-continuous extrusion of mixtures of materials and operate in two 
stages: firstly, the extrudable mass is inserted into the barrel and consolidated; 
secondly, a load is applied to the ram, forcing the extrudable mass to cross through 
the die and produce the extrudates. 
If required, the ram extruders can be instrumented with a load cell, 
allowing recording of the applied loads and the ram displacements during processing. 
The moving speed of the ram (extrusion rate) can be adjusted. 
 
1.3.4.  Shapes of extrudates 
The extrudates and co-extrudates can have different shapes 
depending on the features of the extrusion dies used. The most common ones are 
the rod or cylindrical and tubular shapes (58-61). However, there is also the 
possibility of manufacturing extrudates with a laminar shape (55). 
 
1.3.5.  Materials for extrusion 
A vast range of materials can be used for preparing extrudates and co-
extrudates. The selection of materials, their combination and proportions in the 
formulations, has an impact on the properties of the extrudates. In some cases, 
specific materials are preferred with the aim of obtaining extrudates with specific and 
desired properties. For example, the change or substitution of a single excipient in a 
formulation may result in a change of the release rate for the same drug (62). 
In the extrusion or co-extrusion processes the materials are used with 
different purposes or functions. In general, all formulations include fillers, binders, 
lubricants and disintegrants. However, if needed, surface-active agents, pH 
adjusters, release modifiers or cosolvents, amongst others, can also be included to 
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modify the properties of extrudates. Additionally, solvents are often used as extrusion 
aids, especially water, which is the most commonly used solvent in extrusion (55). 
In some cases, it is necessary to include complementary materials 
with similar functions (e.g. a combination of two or more binders). Additionally, the 
proportions of the materials can influence and define their main roles in the 
formulation. For example, lactose is considered filler if present in a fraction higher 
than 50%, while is considered disintegrant when lower than 10%. 
Fillers are mainly used to increase bulk. Lactose, dicalcium 
diphosphate, mannitol, and starch and its derivatives, are examples of fillers. 
Binders are used to assure mass cohesiveness during processing and 
contributing for the integrity of the extrudates after manufacture. Some of them 
absorb and retain water facilitating the wet extrusion process and improving further 
spheronization. Microcrystalline cellulose, polyvinylpyrrolidone, gelatin, starch, 
hydroxypropylmethylcellulose, methylcellulose, hydroxypropylcellulose, sodium 
carboxymethylcellulose, carbomer, and chitosan have been used as binders. 
Lubricants improve the ability of the mixtures of materials for extrusion, 
and glidants facilitate the movement of the extrudable masses over the surfaces of 
the extruders, contributing for the success of the extrusion process. Light mineral oil, 
sodium stearyl fumarate, colloidal silicon dioxide, hydrogenated castor oil, and 
glycerol behenate, amongst others, are used as lubricants or glidants. 
Disintegrants (e.g. croscarmellose sodium and sodium starch 
glycolate) accelerate the release of drugs from extrudates by facilitating the 
destruction of the extrudates and co-extrudates when in contact with water. 
As referred previously, the extrudates can be used for controlling the 
release of drugs as it is possible to obtain immediate (42), sustained (63) or retarded 
(47) releases. Also, it is possible to target the release of a drug (48). This control of 
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release is a powerful advantage of the dosage forms manufactured via extrusion or 
co-extrusion. 
Powdered cellulose and carrageenans have been used as extrusion 
aids producing extrudates with fast drug releases (64, 65). Chitosan and carbomer 
are examples of materials used to promote a sustained release (release modifiers). 
Lipids and lipid-based materials have also been included in 
formulations for extrusion, especially due to their binding properties, but also as 
lubricants. Waxes, mono- and diglycerides, polyglycolised glycerides, amongst 
others, allow the manufacture of extrudates. These lipid materials have been applied 
in the process of extrusion avoiding changes in temperature and avoiding the 
inclusion of solvents for facilitating the extrusion process. The use of lipid materials 
for extrusion has been considered very promising (42). 
 
1.3.5.1. Materials for extrusion at room temperature, in the absence of 
solvents 
The majority of the commonly used excipients for extrusion and co-
extrusion do not allow the processing at room temperature and in the absence of 
solvents. 
Lipid-based materials with low melting ranges such as fatty acids, 
mixtures of fatty acids with polyethylene glycols, mixtures of triglycerides with low 
and high melting ranges, and glycerides, have been tested and proved to be 
promising for extrusion at these conditions (66-68). 
 
1.3.5.2. Formulations for extrusion 
The process of creating formulations suitable for extrusion consists, in 
the majority of the cases, a trial and error exercise. The main objective to achieve 
when combining the different materials is to obtain a cohesive and plastic extrudable 
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mass, which preserve its homogeneity during the entire extrusion procedure. 
Additionally, the mixture of materials must have a suitable flowability during 
processing, be non-adhesive and produce rigid extrudates that preserve their shape 
after manufacture and during storage. 
 
1.3.6.  Process of extrusion and co-extrusion 
Extrusion, as well as co-extrusion, allows the manufacture of 
pharmaceutical dosage forms with quality. After the identification of the composition 
of the formulation and the proportions of the components, it is necessary to define 
appropriate operational and processing parameters in order to obtain products with 
the desired properties. Also, the extrusion process must be well characterized and 
described, contributing for the definition of the best operational conditions. 
Additionally, several other pharmaceutical operations, such as milling or sieving, 
amongst others, might be applied simultaneously, contributing for the success of the 
extrusion process. 
 
1.3.6.1. Operational parameters and equipment features 
When developing an appropriate formulation, it is important to define 
the most adequate operational parameters in order to obtain the necessary 
processing conditions. The extrusion rate, the temperature of processing and the 
design and features of the die(s) have a decisive influence and impact on the quality 
of extrudates. 
Higher extrusion rates may promote the cohesion of the materials 
instead of producing excessively soft extrudates, which break easily and present 
major quality defects. Also, higher extrusion rates may increase the stability of the 
structure of the obtained extrudates. However, high extrusion rates may originate or 
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facilitate the appearance of severe surface imperfections or defects, such as the 
sharkskin (69). 
The temperature of processing and of the equipment, that might be 
slightly different, also influences the final properties of the manufactured extrudates. 
The increase on temperature may determine a partial or complete melting of the 
materials, promoting a more efficient mixing over processing. Additionally, the cooling 
process may also have an impact on the properties of the extrudates, as changes in 
temperatures always change the properties of the materials and, in consequence, of 
the manufactured products.  
The design, shape and characteristics of the extruding dies also have 
a decisive influence in the final properties of the extrudates and co-extrudates. 
Specific shapes of the die may produce products that are not sufficiently consistent, 
or that contain surface defects resulting from an irregular flow of the extrudable 
masses inside the extrusion chambers and/or the occurrence of an excessive friction 
on the extruder walls and surfaces. 
 
1.3.6.2. Characterizing the extrusion process (extrusion profiles) 
During the extrusion and co-extrusion processes it is possible to build 
up an extrusion profile with the applied loads to the extrudable masses in function of 
the displacement of the ram. The obtained extrusion profiles allow characterization of 
the process of extrusion. 
A typical extrusion procedure originates profiles with three different 
regions or stages: the compression, the steady-state and the forced flow stages. In 
the compression stage occurs a large change in the displacement of the ram but a 
small change in the load applied to the extrudable mass, as the ram is descending 
and consolidating the materials into a plug with the minimum volume and highest 
density. At this point, there is an abrupt increase in the load and a minimal change in 
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the displacement, while the material density remains unaffected. The compression 
stage ends when the pressure applied to the extrudable mass is sufficient for the 
material start the flow through the die. The beginning of the flow is followed by the 
steady-state flow period in which the force required for maintaining the extrusion 
process remains constant as the displacement increases. At the end of the process, 
when the steady-state stage and the extrusion conditions are no longer possible to 
be maintained, there is a forced flow stage. In this stage, there is an increase in the 
force with the displacement caused due to the close approach of the ram to the die 
surface. 
Generally, the extrusion procedures that produce extrudates with the 
desired quality, present long steady-state stages, with constant and small variations 
of forces applied during that period. 
 
1.3.6.3. Other manufacturing operations involved 
The manufacture of extrudates requires the use of technological 
operations that complement the extrusion process itself, contributing for the quality of 
the extrusion process and of the obtained products. 
In the majority of the cases, the milling and/or sieving of the starting 
materials are operations essential for allowing the further preparation of quality 
extrudates, as the control and calibration of the particle size of the starting materials 
might have an impact in the properties of the final products. 
Additionally, the mixing operations and proper homogenization of the 
materials composing the extrudable masses is essential for guaranteeing the 
homogeneity of the manufactured extrudates. 
In some cases, the drying and organic solvent removal operations can 
also be indispensible for preparing extrudates with the desired features after 
manufacture and in a long-term perspective. 
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1.3.7.  Characterization and properties of extrudates and co-extrudates 
The characterization and assessment of the extrudates and co-
extrudates is important for understanding the impact of the operating conditions on 
the properties of final products. Several properties can contribute for describing the 
main features of a certain extrudate, namely the physical and mechanical properties. 
 
1.3.7.1. Surface 
The surface of extrudates and co-extrudates must be homogeneous, 
uniform and smooth. The existence of any surface imperfections or defects can 
cause fragmentation. 
The sharkskin defect is considered one of the most typical surface 
defects of extrudates. The shark-skinned extrudates present similar features than a 
ridge-like spiral structure, which occurs in a transversal direction to the extrusion 
flow. The sharkskin defect is caused by flow instabilities during extrusion at the entry 
and/or at the exit of the die, and can be resolved or minimized by adjusting the rate of 
extrusion (70). 
Extreme sharkskin normally results in fragmentation or complete 
breakage of the extrudates. Additionally, extrudates can present rough surfaces, 
representing less severe defects, which also have an impact on the quality of the 
extrudates. Shark skinning is promoted by short die lengths and by low extrusion 
rates. Therefore, an increase in the length and/or in the extrusion rate can improve 
quality of extrudates and result in smooth surfaces. 
Also, the surface quality of extrudates and the occurrence of surface 
defects depends on the components included in the formulations. Therefore, surface 
defects can be controlled from the very beginning, during the formulation 
development stage. In general, the inclusion of binding agents improves the quality of 
the extrudates by reducing the possibility of occurrence of surface defects. 
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1.3.7.2. Thickness 
The measurement of the thickness at different regions of the 
extrudates and co-extrudates provides information over the regularity of its shape. 
The thickness must be regular and uniform throughout the entire extrudates. 
The extrudate composition, the features of the extrusion die and of the 
extruder walls, and of the extrusion procedure, namely the extrusion rate and 
temperature, may influence the thickness of the extrudates and co-extrudates, as it 
may influence the expansion of the materials right after extrusion, when exiting the 
extrusion die. This expansion phenomenon must be considered and studied for all 
extrusion formulations and procedures. 
 
1.3.7.3. Density and porosity 
When the extrudable materials are subjected to high and intense 
pressures or extrusion loads, there are changes in the density and porosity of the 
extrudates and co-extrudates. Therefore, the density and porosity of the 
manufactured products must be controlled over the extrusion procedure and must 
remain unchanged over storage, so that the extrudates properties are maintained. 
 
1.3.7.4. Mechanical properties 
As referred previously, when the extrudable masses are subjected to 
high extrusion loads, there are observed changes in the extruded materials that have 
an impact in the final extrudates. 
The assessment of the mechanical properties of the extrudates and 
the analysis of its evolution over time is very important for concluding over the quality 
of the obtained products. 
The bending strength, the deformation, the stiffness, and the Young’s 
modulus of elasticity always bring very relevant data about the extrusion process 
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and, more importantly, complement all the physical information collected of each 
extrudate. 
 
1.3.7.5. Thermal behavior 
The analysis of the thermal behaviour of both starting materials and 
obtained extrudates is important for concluding over the overall properties of the 
extrudates. The raw materials composing the formulations will have a decisive 
influence on the final products, as their properties will shape the properties of the 
extrudates. Therefore, a careful and complete study of the properties of each raw 
material available is essential when designing the formulations in order to select the 
most adequate materials for obtaining products with the specific and desired 
features. 
Additionally, the assessment of the thermal behaviour of the 
extrudates after the manufacture and over storage contributes with important 
information for concluding over the physical and mechanical properties of the 
extrudates. In the majority of the cases, the changes identified in the thermal 
behaviour of a certain extrudate, correlate with changes in the physical and/or 
mechanical properties of the extrudates. 
 
1.3.8.  Further processing of extrudates 
Extrudates and co-extrudates can be further processed into solid 
dosage forms such as pellets, tablets (prepared from pellets), suppositories, implants 
and others (54, 71). 
The manufacture of pellets of uniform shape, size and density, 
containing one or more drugs, has been considered the most important application 
for extrusion and co-extrusion. The pelletization process involves a sequence of 
operations: blending of powdered materials, wetting of the mass by adding a liquid 
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binder, extruding (or co-extruding) by pressing the moistened mass through an 
extrusion die, spheronizing with a fast-rotating friction plate and drying. The extrusion 
of a wet mass originates an intermediate spaghetti-like product, which is spheronized 
to yield a spherical product (50). 
The obtained pellets can be coated. In general, the coating is applied 
for guaranteeing a sustained release of the drug(s) or for targeting the drug(s) to 
specific absorption regions of the gastrointestinal tract (e.g. enteric-coated or colon 
targeted delivery) (51). Also, the obtained pellets can be transformed into tablets 
(72). 
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1.4.  Model drugs 
The model drugs selected for this study – coumarin and levothyroxine 
– were specifically used in certain parts of the laboratorial work and, at a later stage, 
the coumarin particles manufactured via RESS were included in the formulation of an 
extrudate for combining the benefits of both technologies. 
 
1.4.1.  Coumarin 
Coumarin is a naturally occurring substance, which is part of several 
plants and essential oils, such as tonka beans, sweet clover, oil of cassia, and 
lavender, amongst others (73). 
Coumarin (1,2-benzopyrone) is a white crystal with an odor similar to 
vanilla at room temperature (molecular weight: 146.15 g/mol; melting point: 68-70 ºC; 
boiling point: 297-299 ºC). Coumarin is composed of an aromatic ring fused to a 
condensed lactone ring. Coumarin is freely soluble in ethanol, chloroform, diethyl 
ether and oils and is slightly soluble in water (74). 
Coumarin is used in medicinal products due to its bronchial dilator, 
anti-inflammatory and analgesic properties. Also, coumarin has been tested and 
evaluated for the treatment of cancer, as a HIV inhibitor and in the treatment of 
lymphedema and venous insufficiency (75, 76). 
 
1.4.2.  Levothyroxine (free acid) 
Levothyroxine (T4) is a synthetic hormone orally administered for the 
treatment of hypothyroidism and goitre. Levothyroxine has a molecular weight of 
776.87 g/mol, a melting point of 231 ºC and is slightly soluble in water (0.105 mg/L at 
25 ºC). Levothyroxine has been previously administered through the skin, especially 
in cosmetic creams to reduce deposits of adipose tissue on skin (77). 
  
 
 
 
 
 
 
 
 
CHAPTER 2 
 
 
 
Characterization of coumarin particles 
micronized by the rapid expansion of 
supercritical solutions (RESS) technique 
 
 
 
Adapted from: 
Influence of process variables on the properties of coumarin particles micronized by 
supercritical fluids (RESS) to be delivered in a laminar extrudate, G. Oliveira, 
J. F. Pinto, AAPS PharmSciTech (2015).  
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2.1.  Introduction 
In recent years, technologies using fluids in the supercritical state have 
been increasingly considered in the pharmaceutical field with several applications, 
especially for the extraction of substances from natural products and for the 
manufacture of drug particles with small sizes (78, 79). The reduction of the particle 
size enhances the bioavailability of the drugs, one of the major challenges when 
developing new pharmaceutical dosage forms, since it results in the increase of the 
specific surface area of the powdered drugs, promoting their dissolution in the 
biological fluids (19). 
Various strategies and technologies have been applied on improving 
the dissolution of poorly water-soluble drugs, particularly those related to size 
reduction of particles (4, 80). 
Comparing with other micronizing methodologies – such as the 
mechanical comminution of larger particles (top-down approach) via dry or wet 
milling (81), or the controlled association of a molecularly dispersed drug (bottom-up 
approach) by spray-drying (82), freeze-drying (7) or controlled crystallization (83) – 
the supercritical fluids (SCF) technologies present important advantages, as they 
reduce the possibility of occurring undesired phenomena, namely chemical or 
thermal degradation due to mechanical action (84), occurrence of polymorphic 
transitions and formation of amorphous states of the drug (85). Furthermore, SCF 
technologies avoid the usage of large amounts of solvents, eliminating the presence 
of solvent residues in the final particles or the need for special environmental 
protection measures.  
Lately, the Rapid Expansion of Supercritical Solutions (RESS) 
technique has been one of the most used SCF technologies in the micronization of 
drugs such as gemfibrozil (17), diclofenac (86) and nabumetone (14), amongst 
others. It has been applied in the design of drug particles, as it allows the control of 
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the manufacturing process by designing the most suitable formulations and 
processing parameters in order to obtain drug particles with desired attributes, 
particularly reduced sizes, narrow size distributions and homogeneous morphologies 
(19, 87). 
In the RESS manufacturing processes, the experimental conditions 
influence the physical and/or chemical properties of the obtained particles (86, 88-
90). Understanding the effect of the processing conditions (e.g. operation in a 
continuous or discontinuous mode) is paramount for designing particles with required 
features (18). 
For this study, coumarin was selected as model drug, as it has been 
tested as therapeutic agent in various types of cancer (91). 
 
2.2.  Aim of study 
This study aimed at manufacturing and characterization of particles of 
coumarin with controlled and reduced sizes using the rapid expansion of supercritical 
solutions (RESS) technology. 
 
 
2.3.  Materials and methods 
 
2.3.1.  Materials 
Coumarin from Sigma-Aldrich (Germany) was the starting material for 
the manufacture of particles with reduced sizes. In the RESS experiments, the gas / 
solvent used was carbon dioxide (CO2, MW 44.01 g/mol, Air Liquid, Germany). 
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2.3.2.  Methods 
 
2.3.2.1. Manufacture of coumarin particles 
Prior to micronization, raw coumarin (20 g) was milled in a laboratory 
size pearl-ball mill (10 cm diameter with 4 balls with a 2 cm diameter) for 120 min 
(350 rpm at 23 ºC). 
The rapid expansion of supercritical solutions (RESS) technique was 
considered in both the discontinuous mode (experiments 1-10), considering specific 
initial quantities of coumarin (2, 10, 15 or 20 g), pre-expansion temperatures (40 or 
60 ºC), pre-expansion pressures (15-35, 25-35, 15-25 or 35-42 MPa) and post-
expansion pressures (0.1, 2.5 or 5.0 MPa), and the continuous mode (experiments 
11-15) also considering specific initial quantities of coumarin (25 or 50 g), two flow 
rates of carbon dioxide (1-2 or 11-12 kg/h) and different expansion periods (0.5, 4.0 
or 5.0 h) (Table 2.1). 
Experiments were carried out in a multipurpose pilot unit for high-
pressure micronization (SITEC-Sieber Engineering AG, Maur / Zürich, Switzerland). 
For further description on the equipment’s operation the reader is referred to the work 
by Türk et al. (19). 
In the discontinuous mode of operation, coumarin was placed in the 
extraction chamber (volume of 730 cm3) before heating (pre-expansion temperature) 
and the internal pressure increased (pre-expansion pressure) by injecting carbon 
dioxide into the chamber. Both temperature and pressure were maintained for a 
specific period of time (extraction time) allowing the dissolution of coumarin. Then, 
the solution of coumarin in CO2 was transferred through a nozzle (d = 150 µm) to the 
expansion chamber, set at defined conditions (post-expansion temperature and 
pressure), allowing the collection of particles in a collector. To prevent the decrease 
of pressure in the extraction chamber below the critical pressure, the process of 
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transferring was interrupted at the minimum pre-expansion pressure to prevent 
solubility problems of coumarin in supercritical carbon dioxide. The pressure in the 
extraction chamber (internal pressure) was then increased to the initial pre-expansion 
pressure by injecting fresh carbon dioxide into the chamber, completing one 
expansion cycle. 
 In the continuous mode of operation, coumarin was placed in the 
extraction chamber (volume of 730 cm3) and the internal temperature and pressure 
increased. Once both predefined temperature and pressure were reached in the 
extraction chamber, the supercritical solution of coumarin in carbon dioxide was 
immediately and continuously transferred through the nozzle (d = 150 µm) to the 
expansion chamber set with a specific temperature and pressure allowing the 
continuous collection of particles in a glass collector. The pressure in the extraction 
chamber was kept constant by the continuous injection of fresh carbon dioxide. The 
operation was carried out under constant pressure and temperature conditions for a 
specified period of time with continuous production of particles (Table 2.1). 
The quality of the process of manufacturing particles was evaluated 
based on the yield of the process, defined as the ratio between the mass of collected 
coumarin particles after production and the initial mass of raw coumarin used. 
 
2.3.2.2. Characterization of particles 
The size and size distribution of coumarin particles was determined by 
laser diffractometry (Mastersizer 2000, Hydro S dispersion unit, Malvern Instruments, 
UK). The samples were dispersed in a saturated aqueous solution of magnesium 
sulphate (filtered supernatant) to prevent dissolution of coumarin. Measurements 
(n=3) were carried out considering the refractive indexes of materials (water: 1.33; 
coumarin: 1.66), obscuration limits (between 0.5-10 %), stirring speed of suspension 
(1750 rpm), intensity of ultrasounds (50 %, 10 s before each measurement), 
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background measurement time (10 s), sample measurement time (10 s), delay 
between measurements (10 s) and number of measurement cycles (10 cycles). 
The median (d50), percentiles (d10 and d90) and span [(d90-d10)/d50] 
were considered for the characterization of size and size distribution of each 
population of particles manufactured. Particles of coumarin were also observed by 
optical microscopy (BX51 Microscope, Olympus Corp., Japan). 
The specific surface area of coumarin particles was determined by gas 
adsorption based on the Brunauer, Emmett and Teller (BET) methodology. Samples 
(2-3 g, n=3) were accurately weighed and analyzed on a SA 3100 Beckman Coulter 
system (Beckman Coulter Inc., Germany). The surface area was calculated using the 
SA-VIEWTM software (2.12 version). The morphology of particles of coumarin (raw 
material, RESS and milled) were analyzed by optical microscopy (BX51 Microscope, 
Olympus Corp., Japan) and scanning electronic microscopy (DSM 940, Carl Zeiss, 
Germany, with a sputter coater, E 5100, Bio-Rad, München, Germany). 
The densities of coumarin particles were determined by helium 
pycnometry (AccuPyc 1330, Micromeritics, USA) at room temperature (23±2 ºC) 
(n=3). 
The coumarin particles were tested for thermal behavior right after 
manufacture by differential scanning calorimetry (Q200, TA Instruments, USA). 
Samples (3-6 mg, n=3) were placed in hermetic sealed aluminium pans and tested at 
10 ºC/min between 60-80 ºC. Enthalpies of fusion were calculated for each sample. 
After manufacture, coumarin particles were analyzed by X-ray 
diffractometry for amorphicity behavior. Samples were mounted on an aluminium 
holder and analyzed in a Philips PW1730 diffractometer with automatic data 
acquisition (APD Philips v.35B). The diffractograms were recorded at room 
temperature in the range 10°<2θ<35° and data collected in a continuous mode, with 
a step size of 0.015° (2θ) and an acquisition time of 1.5 s/step. 
  
 
 
Table 2.1: Experimental conditions for discontinuous and continuous modes of operation for the manufacturing of RESS particles. 
 
Experiment 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Initial amount 
of coumarin (g) 
2 10 15 20 10 25 50 
Extraction 
time (h) 
3 NA 
Pre-expansion 
pressure (MPa) 
15-35 15-25 15-35 15-25 15-35 15-25 
Pre-expansion 
temperature (ºC) 
60 40 60 40 
Post-expansion 
pressure (MPa) 
0.1 2.5 5 4 
Post-expansion 
temperature (ºC) 
35 50 
Expansion 
cycles 
4 NA 
Flow rate of CO2 
(Kg/h) 
NA 1-2 11-12 1-2 
Expansion 
period (h) 
NA 0.5 4.0 5.0 0.5 4.0 
 
NA = Not applicable 
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2.3.2.3. Analysis of data 
Data was analyzed by an ANOVA (one-way analysis of variance) 
study for a level of confidence of 99 % and complemented by Tukey’s HSD test 
(statistical significance considered for p < 0.01). 
 
2.4. Results 
 
2.4.1. Properties of coumarin particles 
Both RESS and milling processes produced particles with reduced 
sizes but without showing a distinct shape or morphology, although RESS and milled 
particles (Figure 2.1, A-B) resemble more spherical than the non-treated commercial 
particles, the latter with markedly edges (Figure 2.1, C). 
The median sizes of RESS (between 18.7±0.8 and 61.0±0.7 µm) and 
milled (85.5±1.9 µm) particles were significantly smaller by comparison with non-
treated coumarin (725.1±57.2 µm) (Table 2.2). The span values for different 
populations of particles (1.5-2.6) revealed that RESS particles were not significantly 
different than raw coumarin (1.7), whereas milled particles presented always a higher 
span (2.6) (Table 2.2), i.e., some RESS experimental conditions enabled the 
production of narrow size distributions whereas milled particles produced particles 
with wide distributions (Figure 2.2). In line with these observations RESS particles 
showed a specific surface area between 0.282 and 0.423 m2/g, milled particles of 
0.274 m2/g and non-treated particles 0.175 m2/g (Table 2.2). 
Worth to mention that both RESS and milled particles agglomerated, 
whereas non-treated particles remained individualized and loose (Figure 2.1, A-C) 
suggesting that an increase on the surface area and/or modifications due to 
processing increased their cohesiveness. 
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Figure 2.1: Images of coumarin particles manufactured by RESS 
(Experiment 13) (A), milled from raw particles (B) and raw commercially 
available particles (C) obtained by optical microscopy. 
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Table 2.2: Manufacturing yield, amount of coumarin left in the extraction chamber, particle size distribution, density, surface area and 
enthalpy of fusion of the manufactured coumarin particles. 
 
Coumarin sample 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Milled Commercial 
Manufacturing Yield 
(%) 
10 42 45 35 18 12 17 14 73 60 8 43 70 2 56 NA NA 
Coumarin left in 
extraction chamber (%) 
0 0 0 0 0 0 0 0 0 0 32 10 10 21 23 NA NA 
Particle size 
distribution 
a
 
D10 (µm) 7.8±0.3 11.7±0.8 12.2±0.2 12.2±0.2 16.9±0.1 11.7±0.1 14.5±0.2 22.5±1.0 12.3±0.9 18.2±0.4 12.3±0.2 9.7±0.1 12.2±0.1 9.9±0.3 10.7±0.9 32.2±0.8 185.3±15.6 
D50 (µm) 18.7±0.8 24.8±1.2 32.0±0.7 32.9±0.6 39.2±0.5 26.8±1.2 33.3±1.8 61.0±0.7 37.5±1.0 55.4±0.4 33.3±1.2 26.3±0.7 25.8±0.4 25.4±2.5 38.0±1.8 85.5±1.9 725.1±57.2 
D90 (µm) 57.0±4.6 51.7±0.7 86.0±4.0 79.9±2.6 89.3±4.6 60.0±6.1 80.8±5.1 140.4±4.2 90.4±1.9 134.5±1.4 88.5±10.1 73.2±1.8 52.1±1.1 47.2±8.4 101.6±3.0 251.2±14.8 1436.0±45.9 
Span 
(D90-D10) /D50 
2.6 1.6 2.3 2.1 1.8 1.8 2.0 1.9 2.1 2.1 2.3 2.4 1.5 1.5 2.4 2.6 1.7 
Density 
a
 (g/cm
3
) NA 1.34±0.00 1.36±0.00 1.35±0.00 1.34±0.00 1.36±0.01 1.33±0.00 1.35±0.00 1.32±0.01 1.34±0.02 1.27±0.01 1.31±0.01 1.32±0.01 1.34±0.00 1.30±0.01 1.39±0.00 1.39±0.00 
Surface area (m
2
/g) ND 0.353 0.301 0.307 0.339 0.413 0.345 0.423 0.333 0.377 0.362 0.282 0.375 ND 0.332 0.274 0.175 
Enthalpy of fusion 
(mJ/mg) 
128.2 118.4 129.2 131.1 123.6 130.7 125.2 129.3 130.8 120.5 99.7 130 129.2 127.6 129.5 128.7 143.2 
 
a
 n = 3 
ND = Not possible to determine (not enough amount of particles for analysis). 
NA = Not applicable 
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Figure 2.2: Particle size distributions of non-processed coumarin particles 
( ), after milling ( ) and from the RESS experiments 2 ( ) and 13 ( ). 
 
 
Coumarin particles manufactured by RESS were less dense (densities 
between 1.273±0.008 and 1.358±0.004 g/cm3) than milled (1.389±0.001 g/cm3) and 
non-treated (1.394±0.001 g/cm3) particles (Table 2.2), suggesting that packing of 
molecules in the RESS production was lower than the packing in original particles 
which was not modified by milling. 
The analysis of the X-Ray diffractograms showed changes on the 
diffraction angles of some peaks, with lower intensities in the treated particles (Figure 
2.3) suggesting that amorphization occurred in the same level. However, it must be 
pointed out that coumarin is prone to crystallize / recrystallize, thus, it was not 
surprising that milled and RESS particles presented a high degree of crystallinity and 
there were no significant differences in their diffractograms, meaning that all treated 
particles presented similar amorphous contents, although higher than non-treated 
particles. 
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Figure 2.3: X-ray diffractograms of non-processed coumarin particles ( ), 
after milling ( ) and from the RESS experiments 2 ( ) and 13 ( ). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: Thermal behavior of non-processed coumarin particles ( ), after 
milling ( ) and from the RESS experiments 2 ( ) and 13 ( ). 
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The analysis of the thermograms (Figure 2.4) and enthalpies of fusion 
of all types of particles (Table 2.2) did not reveal any relevant changes in their 
thermal behavior resulting from milling and RESS techniques, as mentioned 
previously. 
 
2.4.2. RESS experimental conditions 
The yields of the manufacturing processes tended to increase with the 
increase of the amount of solute placed in extraction chamber at the beginning of the 
process. Additionally, it was observed that the yields reached maximum values with 
high values of post-expansion pressure and that, at the same time, large fractions of 
solute were retained in the expansion chamber and, consequently, were not 
transformed into particles. The processing conditions might have originated a dead 
volume in the expansion chamber rather than in the extraction chamber, where there 
was confirmed the complete extraction of the solutes. 
Regarding the particles manufactured by the discontinuous flow mode 
(Experiments 1-10), the amount of solute (coumarin) in the extraction chamber 
influenced the size of the particles, as there was an increasing trend of the median 
size with the increase of the initial amount of coumarin: particles with median sizes of 
18.7±0.8 µm (2 g, Experiment 1), 24.8±0.6 µm (10 g, Experiment 2), 32.0±0.7 µm  
(15 g, Experiment 3) and 32.9±0.6 µm (20 g, Experiment 4) were collected (Table 
2.2). 
Similarly, when the pre-expansion temperature increased from 40 to 
60 ˚C the populations of particles obtained presented median sizes of 39.7±0.5 
(40˚C, Experiment 5) and 24.8±1.2 µm (60˚C, Experiment 2), respectively, with very 
similar size distributions (Table 2.2). An increase of the temperature in the extraction 
chamber was reflected by a higher dissolution and low viscosity of the supercritical 
solution. 
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In a different set of experiments when the pre-expansion pressure was 
higher than 25 MPa, particles were formed with higher median sizes (between 
33.3±1.8 µm, Experiment 7 and 61.0±0.7 µm, Experiment 8) by comparison to 
experiments in which the pre-expansion pressure did not exceed 25 MPa  
(26.8±0.4 µm, Experiment 6) (Table 2.2). 
When the pressure in the expansion chamber increased from 0.1 to 
2.5 or 5.0 MPa increased the median size of particles from 32.9±0.6 µm (Experiment 
2) to 37.5±1.0 µm (Experiment 9) and to 55.4±0.4 µm (Experiment 10), respectively 
(Table 2.2). 
The influence of the processing conditions on the amplitudes of the 
particle size distributions (spans) of the coumarin particles manufactured in the 
discontinuous mode was neither clear nor revealed relevant trends: changes on the 
initial amount of coumarin (span of 2.6/2 g, 1.6/10 g, 2.3/15 g and 1.6/20 g), pre-
expansion temperature (span of 1.6/40 ºC and 1.5/60 ºC) and pre-expansion 
pressure intervals (span 1.8/15-25 MPa, Experiment 6, 2.0/25-35 MPa, Experiment 
7, and 1.9/35-42 MPa, Experiment 8) did neither affect nor determined any changing 
trend in the size distribution amplitudes. However, an increase of post-expansion 
pressure gave wider size distributions (span of 1.6 for 0.1 MPa, Experiment 2 by 
comparison with 2.1, Experiment 9 and 2.1 for 5.0 MPa, Experiment 10) (Table 2.2). 
Regarding the continuous mode of operation, the manufacturing yields 
ranged from 2 up to 70%, depending on the experimental conditions: higher 
expansion periods, smaller amounts of coumarin in the extraction chambers and low 
carbon dioxide flow rates (Experiment 13) delivered high quantities of product, by 
opposition to low expansion time and high carbon dioxide flow rate (Experiment 14). 
It is also interesting to point out the fact that large percentages of materials were left 
in the extraction chamber (not observed for the discontinuous mode of operation), 
Production of laminar extrudates containing particles of a model drug processed by supercritical fluids 
 
82 
 
which are directly related to small manufacturing yields. Thus, one can assume that 
low yields were dependent on the dissolution of coumarin in the extraction chamber. 
The increase of the initial amount of coumarin did increase the median 
sizes of particles: 26.3±0.7 µm (25 g) and 38.0±1.8 µm (50 g) (Table 2.2). However, 
an increase in the flow rate of carbon dioxide produced particles with smaller median 
sizes – 33.3±1.2 µm for 1-2 kg/h (Experiment 11) and 25.4±2.5 µm for 11-12 kg/h 
(Experiment 14) (Table 2.2) – and an increase on the expansion time also formed 
particles with smaller median sizes: 33.3±1.2 µm (0.5 h, Experiment 11), 26.3±0.7 
µm (4.0h, Experiment 12) and 25.8±0.4 µm (5.0 h, Experiment 13) (Table 2.2). 
The particles manufactured in the continuous mode presented similar 
size distributions (spans) in comparison with particles obtained commercially and via 
the discontinuous mode of operation (Table 2.2). 
As mentioned previously, all other properties of particles prepared by 
RESS, namely the morphology, density, surface area, thermal behavior and 
crystallinity, did not present significant differences with the exception of particles 
produced according to Experiment 11 for which the density and the enthalpy of 
fusion were lower than other articles, suggesting the formation of different particles.  
In the discontinuous flow experiments, the entire amount of solute was 
dissolved and transferred to the expansion unit, as there was not detected any 
coumarin in the extraction unit at the end of the process (Table 2.2). However, in all 
continuous flow experiments, a fraction of solute was not dissolved, as there were 
calculated fractions of unused solute between 10 and 60% (Table 2.2). Also, the 
manufacturing yields of the RESS experiments varied: there were registered low (2-
18 %), intermediate (35-45 %) and high (56-73 %) manufacturing yields (Table 2.2). 
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2.5.  Discussion 
The results obtained proved that both micronizing methodologies – 
bottom-up (RESS) and top-down (milling) approaches – allowed the manufacture of 
particles with a significant reduction in size. As expected, this reduction on particle 
size resulted in increased surface areas of the powders and in increased 
agglomeration ability of particles, which is also promoted by heat generation in some 
cases (e.g. milling) (90, 92). 
The formation of particles through these processes of micronization 
occurred by different mechanisms, depending on the technology used. The formation 
of particles via milling in a ball mill resulted from the breakage of the original 
coumarin particles due to the impact of the pearl balls on the raw coumarin particles 
and due to the collision of the particles with each other and with the walls of the mill 
into smaller particles. However, the formation of particles via RESS occurred through 
a mechanism of fast nucleation of the solute from the supercritical solution during the 
expansion of the latter in the expansion chamber (13). The differences of 
temperature and pressure between the extraction and expansion chambers were 
high, particularly the decrease of pressure, leading to an abrupt super-saturation of 
the solute in the carbon dioxide, which was rapidly transformed into the solid state as 
the carbon dioxide changed to gas leaving the chamber rapidly. These abrupt 
changes resulted in the formation of solid particles with reduced sizes (13). 
The different mechanisms of particle formation are the grounds to 
justify the production of particles with different properties, namely different 
morphologies, particle size distributions or densities. In the case of milled particles, 
the mechanisms of the process justified the production of particles showing a more 
irregular morphology and higher densities by comparison to the particles formed by 
RESS. Milling is also a random process, in which the reduction on particle size 
depends on many variables (e.g. crystal homogeneity or energy of milling) while the 
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RESS process depends more linearly on the process and materials variables, thus 
the latter produces particles with lower size distributions. 
The reduction of crystallinity of all micronized particles, when 
compared to the original particles, probably resulted from the creation of amorphous 
regions mainly at the surface of the particles (case of the milled particles) or from the 
abrupt or extremely fast process of particle growth that occurs in the supercritical 
technologies (case of the RESS particles), impacting the formation of the crystalline 
structure of the particles. However, in both processes there was a preservation of the 
crystalline properties and structure of the particles, as their amorphous / crystalline 
contents and thermal behaviors were similar, likely dependent on the high ability of 
coumarin to crystallize. Both processes were successful in manufacturing particles 
with reduced sizes, thus, higher surface areas than raw material particles. 
When analyzing more judiciously the two RESS processes used in the 
study – the discontinuous and the continuous modes of operation – it was possible to 
confirm that some of the experimental conditions affected the properties of the 
particles. In the discontinuous flow experiments lower fractions of solute used at the 
start originated more concentrated supercritical solutions of coumarin, which 
consequently created particles with larger sizes when the solution was expanded due 
to a higher super-saturation (89). On the other hand, the effect of different processing 
temperatures in the extraction chamber (pre-expansion temperature) on coumarin 
revealed that the temperature did not influence the size distribution of particles, as 
both temperatures allowed the production of supercritical solutions with equivalent 
saturations. Changes in the pressure of the extraction chamber (pre-expansion 
pressure) failed to show a clear influence on the size of particles whereas lower post-
expansion pressures originated particles with smaller median sizes. The pressure 
gradient between the extraction and expansion chambers was far more critical for the 
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precipitation of solid particles than the temperature gradient, which was small 
between the two chambers. 
In the continuous mode of operation, the continuous flow of the 
supercritical solution in the RESS apparatus, together with the inexistence of an 
initial period of dissolution for coumarin might have changed the impact on the 
supercritical solution concentration on the size of the particles, as there was not a 
stabilization of the supercritical solution in the chamber and the dissolution of the 
solute had to occur over the entire manufacturing period. 
The particles manufactured in the continuous mode presented wider 
size distributions, likely due to the use of a higher flow rate of carbon dioxide. High 
flow rates of carbon dioxide produced supercritical solutions with lower 
concentrations than solutions kept in the extraction chamber for different periods of 
time circulating more rapidly in the equipment. Consequently the time of contact of 
the carbon dioxide in supercritical state with the dissolving solute was smaller, which 
might support these observations. 
Additionally, longer periods of contact between the supercritical 
carbon dioxide and the solute resulted in higher amounts of coumarin dissolved in 
the solvent over the time of experiment, as shown by the low yields obtained for low 
expansion periods and high fractions of coumarin remaining in the extraction 
chamber. As observed for experiment 11, in which the expansion period was 0.5 h, a 
high amount of coumarin was not dissolved and remained in the extraction chamber 
by the end of the experiment. 
In the case of the discontinuous flow experiments, the time allowed for 
dissolution (3 h) was sufficient for dissolving the entire coumarin. However, the 
continuous mode revealed a loss of efficiency in the extraction. Shorter expansion 
periods and higher initial amounts of solute might justify this loss of coumarin 
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(remaining in the extraction chamber), as the expansion period had not been enough 
for the entire consumption of the solute. 
The experiments in which higher initial amounts of solute, post-
expansion pressures and expansion periods were used, presented the highest 
manufacturing yields. An increase in the expansion time might minimize or even 
eliminate the loss of raw coumarin left in the extraction chamber. 
From the data collected, it was evident that both approaches 
considered for the RESS technique could have been used to improving the 
dissolution of drugs by the reduction of their particle size and increase on the surface 
area, increasing their solubility and dissolution rates (19). The continuous flow 
experiments were more productive than the discontinuous flow experiments as the 
yield of particles obtained was higher. 
 
2.6.  Conclusions 
The RESS technique was successfully used in manufacturing particles 
of coumarin with reduced sizes (between 20-60 µm, mean values) and high surface 
areas. Both RESS procedures – the discontinuous and the continuous flow operation 
modes – and their specific experimental conditions influenced the properties of the 
manufactured particles, especially the size and size distribution. 
Both RESS operating modes delivered micronized particles but 
optimization was paramount to reach high production yields, small particles size, 
smooth surfaces and less dense and more amorphous particles than the ones 
produced by milling. 
 
 
  
 
 
 
 
 
 
 
 
CHAPTER 3 
 
 
 
Characterization of laminar extrudates 
manufactured at room temperature in the 
absence of solvents 
 
 
 
Adapted from: 
Characterization of laminar extrudates manufactured at room temperature in the 
absence of solvents for the delivery of drugs, G. Oliveira, M. A. Wahl, J. F. Pinto, 
International Journal of Pharmaceutics 454 (2013) 90– 98.  
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3.1.  Introduction 
Extrusion is a technology widely applied in various fields such as 
plastic processing, ceramics, food and pharmaceutical industries (57). In the 
pharmaceutical field, the wet and hot-melt extrusion processes are commonly 
applied in the manufacture of medicines. However, these processes present some 
limitations, namely the use of solvents in the formulations (e.g. water) and/or 
changes on temperature during manufacturing. Due to these limitations, certain 
drugs cannot be processed by extrusion, as they are heat and/or solvent sensitive, 
thus, the possibility of performing extrusion without the use of solvents and changes 
in temperature during processing represents a step forward in the field, allowing a 
wider application and turning this technology into a green process (42). 
Extrudates can have different shapes. The most common ones are the 
rod or cylindrical (59) and tubular (61) shapes. However, there is also the possibility 
of manufacturing extrudates with laminar shape, which might be suitable for oral or 
topical delivery of drugs (55). Furthermore, extrudates with a laminar shape 
manufactured in the absence of solvents at room temperature can be regarded as a 
green technology. 
Only a small number of excipients have been reported as suitable for 
the manufacture of extrudates at room temperature in the absence of solvents. 
Binders and lubricants such as lipid-based excipients with low melting ranges like 
fatty acids (61) and mixtures of fatty acids with polyethylene glycols (PEG) have 
been processed under these conditions (66). Equally, combinations of triglycerides 
with low and high melting ranges allow the manufacture of extrudates at moderate 
temperatures (e.g. 40 ºC), not affecting the stability of the extrudates (67). 
Glycerides, such as glyceryl palmitostearate, glyceryl trimyristate or 
glyceryl dibehenate, can also be used in the manufacture of extrudates with different 
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properties due to their chemical and physical complexity, which lead to distinct 
melting, crystallization, polymorphic and other physical differences (68). 
It follows that the mechanical properties of extrudates manufactured 
from solid lipid-based excipients need to be properly assessed as these extrudates 
may undertake important physical changes throughout storage (93). Lipid-based 
excipients with a heterogeneous composition are more sensitive to formulation and 
processing variations, leading to more evident changes in their structural stability 
throughout time (aging), which can have an impact on the product characteristics, 
such as the release behavior of the drug (93-95). The release of drugs from 
extrudates with such components can be modified with the inclusion of hydrophilic 
materials (e.g. PEG), by changing the surface area of the extrudates (67), by a 
criteria selection of specific lipid-based excipients (e.g. different melting ranges) or by 
considering the use of appropriate combinations of these to manufacture controlled 
release solid dosage forms (96). 
 
3.2  Aim of study 
This study aims to evaluate the extrusion ability of materials by 
laminar extrusion at room temperature in the absence of solvents and the potential of 
the new dosage form to deliver drugs, as well as, to assess the stability of the 
properties of extrudates manufactured over storage. 
 
3.3.  Materials and methods 
 
3.3.1.  Materials 
The materials selected for this study included several solid lipids, 
namely, glyceryl palmitostearate (Precirol™ ATO 5, Gattefossé, France; melting 
range: 69-74ºC), glyceryl trimyristate (Dynasan™ 114, Sasol, Germany; melting 
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range: 53-57ºC), glyceryl dibehenate (CompritolTM 888 ATO, Gattefossé, France; 
melting range: 55-58ºC), hard fat (Witocan™ 42/44, Sasol, Germany; melting range: 
42-44ºC) and mixtures of polyethylene glycol with glycerides (Gelucire™ 33/01, 
Gattefossé, France; melting range: 33-35ºC). These materials are mixtures of 
different lipid components (Table 3.1). Additionally, a mixture of polydimethylsiloxane 
with silicon dioxide (Simethicone™ Q7-2243 LVA, Dow Corning, Belgium) was 
included in all formulations and lactose (SpheroLacTM, Meggle Pharma, Germany) 
was considered as the diluent. The model drug was milled coumarin particles (0-90, 
250-355 and 710-1000 μm), obtained from coarse coumarin (Sigma-Aldrich, Munich, 
Germany) by milling the latter in an analytical grinder (A10 Yellow Line, IKA, 
Königswinter, Germany). 
 
3.3.2.  Methods 
 
3.3.2.1. Preparation of extrudates 
The excipients in each formulation (Table 3.2) were mixed in a 
planetary mixer (Kenwood Chef, Hampshire, UK) for 15 minutes and placed in the 
extrusion chamber. The manufacture of the laminar extrudates was carried out using 
an in-house built ram extruder (Lurga, Sacavém, Portugal) with a specific die 
(1x40mm rectangular cross section) designed to prepare extrudates with a laminar 
shape (Figure 3.1). 
The ram extruder was adjusted to a universal testing machine (LR 
50K, Lloyds Instruments, Leicester, UK) fit with a load cell that allowed collection of 
the applied force and displacement data from the process. Extrudates were 
manufactured at different extrusion rates (100, 300 and 500 mm/min), cut into 
squares (40*40*1mm) immediately after production and stored in a desiccator  
(23 ºC / 30 % RH). 
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Table 3.1: Composition and melting ranges of the lipid-based excipients. 
 
Lipid-based 
excipients 
Fatty acids chain 
length a 
Melting 
range (ºC) 
Observations a 
Polyethylene glycol 
glycerides 
C10 to C18 
(saturated fatty acids) 
33 – 35 - 
Hard fat 
C10 to C18 
(saturated fatty acids) 
42 – 44 - 
Glyceryl trimyristate 
C14 
(saturated fatty acids) 
53 – 57 - 
Glyceryl 
palmitostearate 
C18 55 – 58 
Mixtures of mono (19.1 %), di 
(53.2 %) and tristearate (27.4 %) 
Glyceryl 
dibehenate 
C22 69 – 74 
Mixtures of mono (17.8 %), di 
(53.0 %) and tribehenate (26.8 %) 
 
a
 According to the information provided by the suppliers. 
 
 
Table 3.2: Composition of the formulations considered in the study (%). 
 
Formulation A B C D E F 
Polyethylene glycol glycerides 10 10 4 4 4 4 
Hard fat - 30 - 33 33 33 
Glyceryl trimyristate 30 - 33 - - - 
Glyceryl dibehenate - 30 - 33 33 33 
Glyceryl palmitostearate 30 - 33 - - - 
Polydimethylsiloxane – silicon 
dioxide mixture 
20 20 20 20 20 20 
Lactose 10 10 10 10 5 - 
Coumarin - - - - 5 ª 10 ª 
 
a
 Three different laminar extrudates were manufactured for each formulation containing particles of 
coumarin with three different size ranges: 0-90, 250-355 and 710-1000 μm. 
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Figure 3.1: Schematic representation of the ram extruder used 
to manufacture the laminar extrudates. 
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3.3.2.2. Characterization of extrudates 
 
3.3.2.2.1. Physical characterization 
The extrusion force at steady state (Fss) was calculated for each 
extrusion cycle as the mean of the force points obtained between 70 and 100 mm of 
the piston’s displacement. The dimensions (measured with a caliper) of the 
extrudates manufactured were the thickness (n=10), measured at five distinct points 
to assess the uniformity of each specimen, the width and length of each extrudate 
(originally cut with 40*40*1mm). The densities of both raw materials and extrudates 
(at 0, 1, 2, 3, 7, 10 and 20 days after production) were determined in a helium 
pycnometer (AccuPyc 1330, Micromeritics, USA) at room temperature (23 ºC) (n=3). 
The expected densities of the extrudates were calculated from the densities of the 
raw materials weighted for their fractions in the formulations. The latter have allowed 
the calculation of the porosities of the extrudates, based on the relative decrease on 
the densities of the extrudates, according to the following equation: 
 
                 
                
                   
       Eq. 3.1 
 
Both the raw materials and extrudates were evaluated for potential 
changes due to heat by differential scanning calorimetry (DSC, Q200, TA 
Instruments, New Castle, USA). Samples (3.0-6.0 mg, n=3) were placed in hermetic 
sealed aluminium pans and tested at 10 ºC/min (20-160 ºC). Each sample of 
extrudates was analyzed at days 0, 1, 3, 7, 10 and 20, after manufacture. 
Extrudates (n=3) were characterized for mechanical properties, 
namely by a flexure test at 1, 2, 3, 7, 10 and 20 days after manufacture by a three-
point bend rig test (TA.XT Plus, Stable Microsystems, Godalming, UK) at both axial 
and normal directions of extrusion. Force was applied to the laminar extrudates and 
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both force and displacement were recorded to allow calculation of the bending 
strength, stiffness, deformation and Young’s modulus of elasticity (97). 
The release of coumarin from extrudates was assessed by dissolution 
tests 7 days after their production (Eur. Ph. 2.9.3., n=3, paddle method, 50 rpm, 
phosphate buffer, pH=6.8, AT7 Sotax, Switzerland). The quantification of coumarin 
was carried out by UV spectroscopy at 307 nm (U-2000 Spectrophotometer, Hitachi, 
Japan). To describe the mechanisms of release of coumarin from the extrudates, 
three mathematical models were considered – zero order, Higuchi and Korsmeyer-
Peppas – and their suitability determined, based on their fitting to the data assessed 
by the calculated coefficients of correlation (n=3). The efficiency of dissolution of 
coumarin was determined for all extrudates (98) and the release rates were 
calculated as the best correlation obtained from two separate parts of each curve 
(between 0-3 hours and 4-8 h, following a preliminary analysis of data). A statistical 
analysis was performed based on a one-way analysis of variance (ANOVA) with a 
99% level of confidence and Tukey’s HSD test. Statistical significance was 
considered for p < 0.01. 
 
3.4.  Results and discussion 
 
3.4.1.  Manufacture of extrudates 
As described previously (42), several powdered lipids have been used 
as extrusion binders and lubricants, particularly when solvents are to be avoided. 
Those powdered lipids (glyceryl trimyristate, glyceryl palmitostearate and glyceryl 
dibehenate) have been proven as alternative materials to the commonly used 
excipients in wet and hot-melt extrusions (93). 
The analysis of the extrusion profiles provided information on the 
ability of the formulations to produce extrudates with good quality. Typically, 
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extrusion profiles present three different stages: the compression stage, the steady 
state flow stage and the forced flow stage (57). Long and uniform steady state stages 
were obtained with materials with good extrusion properties and appropriate 
processing conditions (e.g. the right extrusion rate), leading to good quality of the 
extrudates. If uneven extrusion profiles occur, the quality of the resulting extrudates 
is in general poor and various surface defects can be observed (57). 
In this work all extrusion profiles presented typical features (Figure 
3.2): the initial displacement registered a residual extrusion force (compression 
stage) until it reached an abrupt increase of the force indicating the beginning of the 
process of extrusion, which was followed by the steady state flow stage. For all 
extrusion rates, the mean extrusion forces registered at the steady state flow (Fss) 
stage were below 6000 N, and constant over the manufacture of extrudates, prior to 
the onset of the forced flow stage, which proved the satisfactory extrudability of all 
formulations and the production of high quality extrudates (99). 
All mixtures based on different formulations allowed the manufacture 
of extrudates with laminar shape (rectangular cross section) at different extrusion 
rates. Also the different lipid-based extruded masses behaved equally to changes in 
the extrusion rate. It was observed that for formulations A to D (Table 3.2) an 
increase in the extrusion rate corresponded to an increase on the extrusion forces at 
steady state (Table 3.3) and, at the same time, the extrusion profiles became more 
irregular. These observations were expected and resulted from an increase of the 
shear stress at the wall of the die as a reaction to the increase of the ram speed 
reflected by a lower lubrication ability of the formulation to compensate such increase 
on shear stress. Furthermore, a decrease on laminar flow near the die wall shall not 
be excluded (100). 
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Figure 3.2: Extrusion profiles of laminar extrudates from formulations A ( ), 
B ( ), C ( ) and D ( ), manufactured at 300 mm/min. 
 
 
 
Table 3.3: Mean extrusion force (N) at steady state (Fss) of laminar extrudates 
obtained from formulations manufactured at different extrusion rates. 
 
Extrusion Rate 
(mm/min) 
Formulation A a Formulation B a Formulation C a Formulation D a 
100 746 ± 203 r 389 ± 17 r 4429 ± 203 r 932 ± 78 r 
300 1296 ± 142 s 1000 ± 356 r 4566 ± 820 r 1228 ± 222 r,s 
500 1504 ± 68 t 3239 ± 1341 r 5576 ± 130 r 4749 ± 531 s 
 
a
 For each column, the means with different letters in the indices are significantly different (ANOVA; 
p < 0.01; Tukey’s HSD; n=3). 
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In general, the manufacture of laminar extrudates from formulations A 
and B, which contained a higher content of polyethylene glycol glycerides (10%), 
required lower Fss, by comparison with the ones observed for formulations C and D 
(only 4%), turning evident that polyethylene glycol glycerides promoted an easier 
extrusion. This might have occurred due to the lowest melting range of polyethylene 
glycol glycerides (33-35ºC) resulting from the composition of the material, which is a 
mixture of saturated fatty acids with a high variety of chain lengths (between 8 and 
18 atoms of carbon) and, consequently, softened (i.e., for the purpose of this work 
became less viscous), thus, turning the mixture more fluid at lower forces (66). 
Additionally, laminar extrudates obtained from formulation C, which 
contained two lipid excipients with a melting range within the ones for the other 
excipients (glyceryl palmitostearate: 53-57ºC; glyceryl trimyristate: 55-58ºC), required 
higher Fss by comparison with the ones observed for formulation D extrudates, which 
included a mixture of two lipid-based excipients, one with a higher melting range 
(glyceryl dibehenate: 69-74ºC) but another with a lower melting range (hard fat: 42-
44ºC). The effect of the simethicone and lactose in the extrudability of the masses 
was not relevant based on the differences observed, as their contents were kept 
constant throughout the experiments. This suggests an interaction between the liquid 
simethicone and lactose, a material that shall remain in the solid state over the 
process of extrusion. One can suggest that simethicone provided some lubrication 
for the extrusion of lactose particles. 
The mixture of glyceryl dibehenate and hard fat improved the 
extrudability of the masses, whereas the inclusion of both glyceryl palmitostearate 
and glyceryl trimyristate produced a mass with higher difficulty to be extruded 
reflected by the higher forces observed at steady state. An increase in the length of 
the carbon chains of the fatty acid corresponds to an increase in the melting range of 
the lipid and, thereby, to a decrease on the extrudability of the masses (66). 
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Saturated fatty acids with longer chains interacted more strongly and, thereby, 
required higher forces for extrusion whereas lipid-based excipients containing a high 
variety of saturated fatty acids were easier to extrude and required lower forces, 
suggesting an easier softening, if not melting, of the component with the lowest 
melting range. Additionally, these melting ranges can vary within the same lipid 
material as a function of the possible existence of different polymorphic forms (66). 
Thus, the melting ranges of excipients is paramount for this type of process of 
extrusion, as the composition of each lipid-based material included in the 
formulations, especially the length of the carbon chain of the saturated fatty acids, 
plays a major effect on the process of extrusion. Thus, appropriate lipid-based 
excipients and their mixtures must be carefully selected to achieve both a 
satisfactory process and product (42). 
For the manufacture of extrudates including coumarin particles, only 
one of the four initial formulations (A – D) was selected and also only one extrusion 
rate for it’s processing. Formulation D was elected for further analysis and inclusion 
of the drug, as it allowed the manufacture of extrudates without any visual defect 
(see section 3.3.2) and minor changes of the mechanical properties over time of 
storage (see section 3.3.6). Furthermore, the extrusion rate of 300 mm/min was 
selected to further develop our study and, therefore, was used in the manufacture of 
extrudates from formulations E and F, though all extrusion rates were suitable for the 
manufacture of the extrudates. 
The extrusion profiles obtained for different manufacturing cycles at 
300 mm/min with formulations E and F, containing coumarin particles with three 
different size ranges, were equivalent to the ones obtained for formulation D. 
However, the extrusion forces at steady state (Fss) registered for these extrudates 
(Table 3.4) revealed that the formulations containing coumarin particles, 
independently of their sizes, required slightly lower extrusion forces at steady state 
Production of laminar extrudates containing particles of a model drug processed by supercritical fluids 
 
100 
 
when compared with formulations that included lactose only. Therefore, one can say 
that coumarin facilitated the process of extrusion, when comparing to lactose 
formulations. A possible explanation for this observation can be based on the fact 
that lactose and coumarin particles have different melting ranges (143-148 and 
68-70 ºC, respectively), which might justify the lower resistance of coumarin particles 
to extrusion that might have soften under the application of the extrusion load. 
 
 
 
Table 3.4: Influence of coumarin particle size on the mean extrusion force (N) 
at steady state (Fss) for the extrusion of excipients into laminar extrudates 
(obtained from formulations E and F, manufactured at 300 mm/min, n=3). 
 
Coumarin size range (µm) Formulation E a Formulation F a 
0 – 90 1013 ± 187 r 1127 ± 166 r 
250 – 355 1077 ± 141 r 869 ± 86 s 
710 – 1000 1334 ± 198 r 844 ± 124 s 
 
a
 Means with different letters (indices) are significantly different (ANOVA; p<0.01; Tukey’s HSD; n=3) 
 
 
 
3.4.2.  Visual inspection of extrudates 
The quality of the extrudates surface, namely a homogeneous and 
smooth surface, can be critical for successfully achieving the intended applications 
for a specific extrudate, namely reproducible dissolution rate of carrying drugs. Due 
to extrusion flow instabilities at the entry and/or at the exit of the die, extrudates often 
present some distortions and surface imperfections that can be visually identified: 
sharkskin defect, roughness or surface scratches and some structural defects such 
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as surface cracks or fractures, variations of shape, lack of homogeneity due to a 
deficient mixing or incorporation of air during extrusion, excessive softness or 
brittleness, amongst others (70). Extrudates obtained from formulations A, C and D, 
at all extrusion rates, were visually similar and did not present any surface defect 
(Figure 3.3.a). However, extrudates B were excessively soft and presented a severe 
sharkskin defect (Figure 3.3.b), likely due to elongation stresses created at the die 
exit (69, 70), resulting in their exclusion from further consideration in other 
experiments. 
 
 
 
a) 
 
 
 
b) 
 
 
Figure 3.3: Example of laminar extrudates with no surface defects 
(formulations A, C, D, E and F) (a) and with surface defects (formulation B) (b). 
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Extrudates including particles of coumarin (formulations E and F) 
presented a visual aspect similar to formulation D, as the partial or complete 
substitution of lactose by coumarin did not change the properties of the extruded 
masses and, consequently, did not have an impact on the process of extrusion or on 
the quality of the extrudates. 
 
3.4.3.  Thickness of extrudates 
All extrudates (A – F) presented a thickness of approximately 1.6 mm. 
There were not relevant differences observed between the thicknesses of different 
extrudates and neither the extrusion rate nor the inclusion of coumarin particles 
influenced the final thickness of the extrudates. 
For a 1 mm width die, extrudates thicknesses were as high as 1.6 mm, 
representing a relaxation of 60%. Afterwards, all extrudates kept their thicknesses 
and no changes were detected over storage. The materials on converging to the die 
were submitted to stresses that were total or partially released on exiting the die. 
This relaxation can be assumed to be constant as there is no effect seen by the 
different formulations. The assumption can be made on the grounds that, contrary to 
elastic materials, which react on removing the force by the ram, plastic materials 
conserve their shape in consequence of the application of a deforming force (101). 
 
3.4.4.  Density and porosity of extrudates 
A decrease on the densities of extrudates A and C over time of 
storage was observed, whereas extrudates D maintained their density. 
Concomitantly, the porosities of extrudates A and C increased with time while 
extrudates D maintained their porosity or presented a slight decrease. These results 
suggest that extrudates with a lower content of polyethylene glycol glycerides (which 
are composed by a mixture of saturated fatty acids with a wide range of chain 
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lengths) are more likely to keep their densities and porosities over time of storage. 
Additionally, the extrudates that included lipid-based excipients with less variety of 
chemical composition and saturated fatty acids with similar carbon chain lengths 
were less likely to show variability of the density / porosity over time of storage, as 
these excipients promote the stabilization of the structures in comparison with other 
mixtures and more complex lipid-based excipients (95). 
The decrease of density and consequent increase of porosity, 
especially observed for extrudates A and C was in line with our previous 
observations about the manufacture and thickness of extrudates. Right after the 
extrusion, the extrudates expanded and their thicknesses were much higher than 
expected, due to an abrupt decrease of the pressure applied to the materials inside 
the extrusion chamber, in comparison with the pressure after the die exit. Although 
changes in the dimensions on the extrudates were not realized, the observed 
decrease in the densities might have been associated with the expansive behavior 
after extrusion: laminar extrudates expanded (their volume increased while the mass 
remained unchanged), resulting on a decrease of the density. This process of 
expansion might have been more prolonged and more intense for extrudates 
obtained from formulations A and C, rather than laminar extrudates from formulation 
D due to the previously referred composition differences, particularly an increase of 
both hard fat and glyceryl dibehenate fractions on the formulation at the expenses of 
polyethylene glycol glycerides. 
This trend was observed for extrudates manufactured at all extrusion 
rates (100, 300 and 500 mm/min). However, higher extrusion rates produced less 
dense and more porous extrudates. Figure 3.4 presents the density and porosity 
over time of storage of extrudates A (data from extrudates C and D is not shown). 
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a) 
 
 
 
b) 
 
 
Figure 3.4: Density (a) and porosity (b) over storage of extrudates A obtained 
at different extrusion rates: 100 ( ), 300 ( ) and 500 ( ) mm/min. 
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The difference between the pressures applied to the extrudable mass 
inside the extrusion chamber and at exiting the extrusion die was relevant and 
increased with the extrusion rate. Therefore, the materials could have suffered a 
more severe expansion phenomenon due to this pressure difference, resulting in less 
dense and more porous extrudates. 
 These changes of density and porosity over time, more evident for 
formulations A and C than for formulation D, were related to the changes of the 
mechanical properties observed for all tested laminar extrudates (see section 4.6, 
Chapter 3) and testify the aging phenomena that occurs with extrudates mainly 
composed of lipid materials (102). 
 
3.4.5.  Thermal behavior of raw materials and of extrudates over time 
The changes on the thermal behavior and enthalpies of fusion 
observed for both extrudates D and F over time (Figure 3.5 and Table 3.5) strongly 
suggest and support the occurrence of an aging phenomenon, which was expected 
to occur in extrudates mainly composed by lipid materials. For both extrudates, the 
enthalpy of fusion increased over time suggesting a stabilization of the structure of 
the extrudates due to changes of the materials, particularly the lipid materials, which 
transform themselves into more stable forms (102). 
 
Table 3.5: Enthalpies of fusion (J/g) of extrudates D and F 
(coumarin 0-90 µm) over time of storage. 
 
Formulation Day 1 Day 3 Day 7 Day 10 Day 20 
D 104.4 107.6 130.9 139.6 142.3 
F 111.6 125.2 151.6 174.1 198.8 
  
Production of laminar extrudates containing particles of a model drug processed by supercritical fluids 
 
106 
 
 
a) 
 
 
 
 
b) 
 
 
Figure 3.5: Thermograms of extrudates obtained from Formulation D (a) and 
Formulation F (coumarin 0-90 µm) (b), and analyzed over time of storage: 
1 ( ), 3 ( ), 7 ( ), 10 ( ) and 20 ( ) day. 
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The comparison between the thermal behaviors of the individual raw 
materials and the extrudates after their mixture and extrusion was not as clear as 
one would anticipate. Over the process of extrusion, materials were subjected to high 
pressures and shear forces and interacted in a non-immediately clear way. 
Consequently, one can expect that the thermal behaviors of the extrudates were not 
a simple sum of the thermal behaviors of the single materials but a far more complex 
result of the effects. These effects were likely to happen at both molecular and supra 
molecular levels of the extrusion process on the materials, reducing the evaluation of 
the outcome to a qualitative assessment. 
Those effects resulted from the high forces applied to the mixtures of 
powders during extrusion and from the generated friction of the extruding materials 
on the surfaces of the extruder and between particles, have determined an increase 
on the temperature that led to changes on the solid state of the materials. 
Afterwards, these materials tend to stabilize and may undertake changes in their 
structure to a greater state of stability (102). These observations can anticipate and 
contribute for the explanation of the changes of the mechanical properties observed 
for all laminar extrudates. 
 
3.4.6.  Mechanical characterization of extrudates 
The use of glycerides and triglycerides in the manufacture of 
pharmaceutical dosage forms presents important limitations related to their chemical 
complexity, which can create a variety of crystalline forms, including metastable 
forms with consequences on the properties and performance of the dosage forms 
manufactured (66). The mechanisms responsible for these changes are either the 
conversion of the triglycerides from unstable or metastable to more stable 
polymorphic forms, or the conversion from the amorphous to the crystalline state of 
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the glycerides. Altogether they are the basis of the ageing phenomena observed with 
these materials (102). 
The occurrence of polymorphic changes during storage in dosage 
forms, mainly made of lipids have been correlated with changes on their mechanical 
properties over time (e.g. tensile strength) (103). 
Figure 3.6 presents the changes of the mechanical properties of 
extrudates A over time of storage (for simplification data from extrudates C and D is 
not shown, as it presented similar patterns). Extrudates manufactured at different 
extrusion rates (100, 300 or 500 mm/min) presented similar changes and all 
observations were equivalent for all formulations regarding the modifications of the 
mechanical properties over time of storage. The overall pattern of the different 
extrudates can be explained by the stabilization over time of storage. The similarity 
between formulations suggests that different combinations of lipids ended up on the 
same final behavior. Variations due to extrusion rate suggest that the lowest rate 
(100 min/mm) allowed the materials to acquire a higher stability in spite of higher 
shear stresses, as discussed previously. 
Extrudates A and C presented wider changes of the bending strength 
over time when compared with laminar extrudates D, reflecting their lower ability to 
resist to the deformation produced from an applied load. However, extrudates D 
showed a higher variability for the bending strength in the first seven days after 
extrusion before reaching a plateau. Extrudates A and C presented an increasing 
bending strength, which did not stabilize with time, as observed for laminar 
extrudates D. 
Extrudates A and C presented a wider increase of stiffness over time, 
reflecting their increased resistance to deformation in response to an applied force 
(rigidity), whereas laminar extrudates D presented a narrow and small decrease of 
stiffness, reaching a stable status. 
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c) 
 
 
 
 
d) 
 
 
Figure 3.6: Bending strength (a), stiffness (b), deformation (c) and Young’s 
modulus of elasticity (d) of extrudates A, obtained at different extrusion rates: 
100 ( ), 300 ( ) and 500 ( ) mm/min. 
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When a force was applied in their middle section, extrudates A 
presented a strong decrease of deformation over time, in comparison with extrudates 
C, which had a mild decrease, and with extrudates D that maintained stable 
deformation behavior during storage. 
While the elasticity kept decreasing after manufacture for extrudates A 
and C (increasing Young’s modulus of elasticity), laminar extrudates D presented a 
mild increase of elasticity over time, reaching a maximum after 10 days of storage. 
Altogether, the mechanical tests considered, different on the 
properties studied, reflected a coherent behavior of the extrudates regarding their 
structures. Hamdani et al. concluded that, in general, the chemical and physical 
complexity of the lipid based materials leads to a complex and difficult to predict 
behavior of the products manufactured with these materials (e.g. physical 
modifications, polymorphism, crystallization or melting) (68). 
Khan and Craig stated that triglycerides could present a partially 
amorphous layered structure, which gradually crystallizes during storage (aging) 
(104). This process of crystallization occurred with a rate dependency on the number 
of carbon atoms in the fatty acid chains: the longer the fatty acid chain, the longer 
would be the crystallization time. Therefore, the composition of extrudates A and C, 
including 60-66 % of glyceryl trimyristate and glyceryl palmitostearate (two glycerides 
with fatty acids with similar and medium carbon chain lengths – C14 and C18), can 
explain the increase on the bending strength and stiffness and decrease on the 
elasticity. These two materials could form stronger molecular interactions between 
their molecules, leading these extrudates to build up more stable structures when 
compared with laminar extrudates D. Extrudates D, made of 66 % of hard fat and 
glyceryl dibehenate (two lipids with significant differences between the chain lengths 
of their fatty acids – C10 to C18 and C22, respectively), might explain the instability 
observed in the first days after extrusion and the lower bending strength and stiffness 
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and the mild increase of the elasticity, resulting in a weaker structure. The 
comparison of either extrudates C or D, with extrudates A, which presented the 
highest fraction of polyethylene glycol glycerides in the formulation (mixture of 
saturated fatty acids with the highest variability of chain lengths, C10 to C18) can 
explain the wider changes verified in the mechanical properties of the former 
extrudates, as polyethylene glycol glycerides are less resistant to the application of 
stress, undertaking wider mechanical changes. For instance, two days after 
extrusion, extrudates A manufactured at 300 mm/min deformed by 2.6 ± 0.0 mm, 
whereas extrudates C and D only deformed by 0.8 ± 0.0 and 1.3 ± 0.3 mm, 
respectively. 
All these results support the hypothesis that changes observed on the 
mechanical properties of the extrudates were closely related to the type of lipids in 
the formulations. The lipid materials progressively changed their molecular 
interactions in order to achieve a more stable state and these physical changes of 
the raw materials were reflected on the stability of the mechanical properties of the 
laminar extrudates. Thus, the increase on the bending strength and stiffness were 
consistent with these changes and aging phenomena, as the materials tend to 
reorganize after the high stress applied over extrusion. Furthermore, the stabilization 
of the extrudates structure after extrusion led to a progressively lower mobility of the 
molecules, which justifies the lower elasticity of the laminar extrudates and, 
consequently, the lower ability of the extrudates to deform. The lipids had different 
behaviors after extrusion, due to their molecular composition and ability to cope with 
the stresses applied in the process of extrusion. Different mixtures of lipid excipients 
and, particularly, different lengths of the carbon chains of the saturated fatty acids, 
resulted in different molecular interactions in the laminar extrudates structure and, 
consequently, in different mechanical properties. Consequently, extrudates needed 
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to have their properties stabilized over a defined time of storage to allow a 
reproducible performance, particularly on drug release. 
The process of manufacture had also an impact on the structure of the 
extrudates and influenced their properties. As an example, the friction of the 
extruding mass on the walls of the extrudate and die can influence the polymorphic 
behavior of the lipid materials during processing and then storage. Due to this 
friction, a thin molten layer was likely to be present on the surface of the extrudates, 
which started to re-solidify when the extrudates have exited the die (66). 
 
3.4.7.  Release of coumarin from extrudates 
The raw materials included in the formulations can greatly influence 
the release patterns of a drug from the extrudates and, consequently, it was 
expected that various mechanisms were involved in the release of the drug, namely 
drug dissolution and diffusion, swelling and erosion of the matrix, or the occurrence 
of a combination of two or more of these processes (51). Lipid materials can act as 
matrix formers, influencing and controlling the release of the drug (105). Thereby, 
broad ranges of release patterns could be obtained by varying the composition of the 
lipid matrix (95). 
As hydrophobic materials were present in the extrudates 
manufactured in the present study, a slow release rate of the drug might have been 
expected, as described in other studies (106). The dissolution of the drug and/or 
lactose at the surface of the extrudates might have increased the porosity of 
extrudates, from which the drug was slowly released as observed previously for 
glyceride bases (107). No evidence was found for swelling or erosion of the 
extrudates, as the extrudates remained intact and did not disintegrate throughout the 
entire time of the dissolution test. 
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In this study, extrudates including different percentages of particles of 
coumarin with different size ranges were manufactured (formulations E and F). None 
of these extrudates released the entire quantity of coumarin as both formulations (E 
and F) released only up to 75% of coumarin in 8 h (Figure 3.7). 
 
 
 
 
 
Figure 3.7: Drug release profiles of laminar extrudates that included coumarin 
particles with sizes less than 90 μm (5%: ; 10%: ), between 250-355 μm 
(5%: ; 10%: ) or between 710-1000 μm (5%: ; 10%: ). 
 
 
 
It was observed that a decrease in the median size of the coumarin 
particles determined an increase in the release rate of coumarin, both for laminar 
extrudates including 5 and 10 % of coumarin (Table 3.6), as smaller particles have a 
higher surface area, accelerating the dissolution of coumarin into the dissolution 
medium. Additionally, an increase in the percentage of coumarin from 5% to 10% 
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also increased drug release rates, when comparing extrudates including coumarin 
particles with the same size range. Although potentially controversial, these results 
strongly suggest that differences in the median sizes of drug particles led to 
differences in the release rate of drugs from laminar extrudates composed mainly by 
lipid-based excipients. As these lipid-based formulations form a solid matrix, the 
particle size of the drug played an important role the release rate by affecting the 
structure of the extrudates, as previously described previously for other dosage 
forms (108). 
 
 
 
Table 3.6: Dissolution efficiency, release rates of coumarin from extrudates 
seven days after manufacture and coefficients of determination (R2) and 
release exponents (n) obtained from Korsmeyer-Peppas dissolution model. 
 
Fraction of 
coumarin 
(%) 
Coumarin 
Particle Size 
(µm) 
Dissolution 
efficiency 
(%) a 
Release rate (mg.h-1) a Korsmeyer-Peppas 
0 – 3 h 4 – 8 h R2 n 
5 
0 – 90 45.7 ± 3.7 m  8.6 ± 1.0 r,u 3.8 ± 0.8 x 0.995 ± 0.005 0.75 ± 0.05 
250 – 355 36.9 ± 4.2 n 6.5 ± 0.6 r 3.8 ± 0.8 x 0.997 ± 0.002 0.79 ± 0.06 
710 – 1000 14.2 ± 2.4 p 2.6 ± 0.6 s 1.5 ± 0.4 y 0.999 ± 0.001 0.75 ± 0.17 
10 
0 – 90 34.1 ± 0.9 n 11.7 ± 0.5 t 6.3 ± 0.3 z 0.997 ± 0.001 0.75 ± 0.01 
250 – 355 30.0 ± 1.1 n 9.3 ± 0.5 t 6.7 ± 0.7 z 0.997 ± 0.001 0.87 ± 0.03 
710 – 1000 20.0 ± 0.9 p 6.4 ± 0.5 u 4.9 ± 0.8 x,z 0.999 ± 0.000 0.87 ± 0.05 
 
a
 For each column, the means in the dissolution efficiency and release rates with different letters in the 
indices are significantly different (ANOVA; p < 0.01; Tukey’s HSD; n = 3). 
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It was also verified that the release rate of coumarin from the 
extrudates decreased with time. For all formulations, the release rate in the first 3 
hours of the dissolution was always higher than the release rate observed between 4 
and 8 hours of the dissolution test (Table 3.6). 
To better describe the mechanisms involved in the release of 
coumarin from these extrudates, several mathematical models could have been 
applied (98). 
In this study, the zero order and the Higuchi models presented 
unsatisfactory R2 values, whereas the Korsmeyer-Peppas model presented R2 
values close to 1 (Table 3.6) and was accepted as a relevant descriptor of the 
release of the drug. As the n parameter of the Korsmeyer-Peppas model had values 
between 0.57-0.93 for all laminar extrudates, coumarin must have been released by 
diffusion and, concomitantly, by structural alterations of the extrudates such as 
relaxation of the matrix, also described as an anomalous transport / non-Fickian 
model (105). In general, the Korsmeyer-Peppas model was the one that better fitted 
the release profiles obtained. However, some laminar extrudates, especially those 
including 10% of coumarin, also presented high R2 values for the zero order model, 
suggesting that coumarin is released almost without affecting the dimensions and/or 
structure of the extrudates. 
 
3.5.  Conclusions 
The manufacture of extrudates with laminar shape at room 
temperature in the absence of solvents is a promising technology to manufacture 
new dosage forms for delivery of drugs. Our study revealed that the raw materials, 
mainly the lipid-based excipients, and consequently the extrudates, undertook an 
aging process materialized in changes in the mechanical properties, density and 
thermal behavior, similar to the aging phenomena previously observed for glycerides 
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and triglycerides. Different formulations with different components or proportions 
gave laminar extrudates with different mechanical properties. The bending strength, 
stiffness, deformation, elasticity and density of the manufactured laminar extrudates 
changed over time depending on the composition and on the extrusion conditions. 
The characteristics of the materials, especially the variety of glycerides 
and fatty acids that compose the lipid-based excipients, had an important influence in 
the mechanical properties of the laminar extrudates. These properties need to be 
stabilized over time, so that the expected performance of the dosage form is not 
altered. 
Laminar extrudates including different percentages of drug and with 
drug particles with different size ranges presented distinct release profiles. Small 
coumarin particles revealed higher release rates from laminar extrudates when 
comparing with larger drug particles. Laminar extrudates composed mainly by lipid-
based excipients had a retardation effect in the release of the drug. Therefore, the 
drug release rates can be modified just by changing the composition of the 
formulations and/or by changing the size of the drug particles that are included in the 
laminar extrudates. 
 
 
  
 
 
 
  
  
 
 
 
 
 
 
 
 
CHAPTER 4 
 
 
 
Delivery of drugs from laminar co-
extrudates manufactured by a solvent-free 
process at room temperature 
 
 
Adapted from: 
Delivery of Drugs from Laminar Co-Extrudates Manufactured by a Solvent-Free 
Process at Room Temperature, G. Oliveira, M. A. Wahl, J. F. Pinto, Journal of 
Pharmaceutical Sciences (2014) 103(11):3501-10. 
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4.1.  Introduction 
Co-extrusion involves the separate preparation of two or more 
mixtures of excipients with drug(s), which are conveyed separately into a die where 
they come together as a co-extrudate with a pre-defined number of layers and shape 
(e.g. laminar, tubular, rod or cylindrical) (27), depending on the extruder features, 
particularly on the extrusion die (109, 110). In the last decade the technology of co-
extrusion has been applied in several areas namely in the ceramics, food, metallurgy 
and polymer industries and, also, in the manufacture of medical devices and 
pharmaceutical products (111). 
In drug delivery, multi-layered extrudates can be used on modulating 
the release of drugs either by producing a multi-modal release (60) or by allowing a 
higher fine-tuning ability on controlling the release of a drug (112) by imposing 
different release kinetics to each layer, depending on the composition of individual 
layers (113). Furthermore, co-extrusion can be considered for the combined delivery 
of drugs in the same dosage form (even if incompatible), which can be present in 
different layers (27). Traditionally, extrusion and co-extrusion of materials is 
accomplished by either using a solvent [e.g. wet masses (114)] or in the absence of 
solvents [e.g. hot (27) or cold melt extrusion (110)]. 
Lipid-based materials such as fatty acids, mixtures of fatty acids with 
polyethylene glycols, triglycerides and glyceride bases (e.g. glyceryl palmitostearate, 
glyceryl trimyristate or glyceryl dibehenate), have been proven as suitable excipients 
for extrusion at room temperature (42, 61, 67, 93), which can be considered a green 
technology. However, the use of these materials represents an important challenge 
to the formulator, as their composition, particularly their chemical and physical 
variability and complexity, can greatly influence the properties of the extrudates due 
to their ability to crystallize or suffer polymorphic changes (68). Therefore, a deep 
knowledge of the properties of these lipid-based starting materials is essential for 
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better predicting and understanding the properties of the extrudates manufactured 
and their stability (i.e. aging over storage (68)). For instance, a higher fraction of lipid-
based materials with a heterogeneous composition can lead to more relevant 
changes on the physical stability of the extrudates over time with a negative impact 
on their performance, particularly on the release rate of the drug (68). 
 
4.2.  Aim of study 
This study aimed at the manufacture of laminar extrudates and co-
extrudates (with one, two or three layers) in the absence of solvents and at room 
temperature with the potential for the delivery of a model drug by the oral or topical 
routes of administration, and to assess the stability of their properties over storage. 
 
4.3.  Materials and methods 
 
4.3.1.  Materials 
Glyceryl dibehenate (CompritolTM 888 ATO, Gattefossé, France), hard 
fat (Witocan™ 42/44, Sasol, Germany), a mixture of polyethylene glycol with 
glycerides (Gelucire™ 33/01, Gattefossé, France), a mixture of polydimethylsiloxane 
with silicon dioxide (Simethicone™ Q7-2243 LVA, Dow Corning, Belgium) and 
lactose (SpheroLacTM, Meggle Pharma, Germany) were used as starting materials for 
the manufacture of the extrudates and co-extrudates. Coumarin particles (0-90 μm) 
milled from coarse coumarin (Sigma-Aldrich, Germany) in an analytical grinder (A10 
Yellow Line, IKA, Germany) were sieved (Vibratory Sieve Shaker, AS 200 digit, 
Retsch GmbH, Germany) before consideration as model drug. 
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4.3.2.  Methods 
 
4.3.2.1. Manufacture of extrudates and co-extrudates 
For each extrudate or co-extrudate layer, the materials (Table 4.1) 
were mixed in a planetary mixer (Kenwood, Hampshire, UK) for 15 min and placed in 
the respective extrusion chamber, according to the type and position of the layers of 
each sample (Table 4.2). The manufacture of laminar extrudates and co-extrudates 
was carried out using a ram extruder (Lurga, Portugal) with a fixed design of 
chambers and dies (Figure 4.1), at defined extrusion rates, which correspond to 
specific mass flow rates (Table 4.2). The ram extruder was fixed to a universal 
testing machine (LR 50K, Lloyds Instruments, UK) fit with a load cell allowing 
recording of the force applied and displacement of the ram. The extrudates and co-
extrudates obtained were cut into squares (40x40mm) immediately after exiting the 
extrusion die and stored in a desiccator (23 C / 30 % RH) prior to characterization. 
 
 
Table 4.1: Density of raw materials and composition of the individual laminar 
extrudate layer. 
 
Materials Density (g/cm3) 
Layer (%) 
A B 
Polyethylene glycol glyceride 0.944 ± 0.001 4 4 
Hard fat 0.999 ± 0.001 33 33 
Glyceryl dibehenate 1.021 ± 0.000 33 33 
Polydimethylsiloxane – silicon dioxide mixture 0.956 ± 0.000 20 20 
Lactose 1.543 ± 0.001 - 10 
Coumarin 1.380 ± 0.001 10 - 
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Figure 4.1: Extruder (a) and extrusion dies used in the manufacture of 
extrudates with one layer (b), two layers (c) and three layers (d). 
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Table 4.2: Composition of laminar extrudates and co-extrudates, extrusion 
rates and mass flow rates. 
 
Extrudate 
Number of 
layers 
Type and order 
of layers 
Extrusion rate 
(mm/min) 
Mass flow rate 
(g/min) 
I 1 A 100 61 ± 3 
II 1 A 300 174 ± 8 
III 1 A 500 299 ± 7 
IV 2 A + B 300 349 ± 12 
V 3 B + A + B 300 448 ± 11 
 
 
4.3.2.2. Characterization of extrudates 
 
4.3.2.2.1. Extrusion profiles and force at steady state (FSS) 
For each extrudate and co-extrudate the extrusion force at steady 
state (Fss) was calculated as the mean of the force values obtained between 100 and 
130 mm of the displacement of the ram. 
 
4.3.2.2.2. Morphological evaluation 
Extrudates and co-extrudates were visually inspected to detect any 
surface defect due to poor process control or formulation inadequacy and observed 
(surface and cross section) by scanning electron microscopy (SEM) using a DSM 
940 scanning electron microscope (Carl Zeiss, Germany). Previously, the samples 
were coated with gold in a Sputter Coater (E 5100, Bio-Rad, Germany). 
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4.3.2.2.3. Thickness of extrudates 
The thickness of cut extrudates was measured using a caliper (n=10) 
at five predefined and distinct points to assess thickness uniformity. 
 
4.3.2.2.4. Density and porosity of extrudates 
The densities of both starting materials and extrudates (at 1, 3, 8, 15, 
30, 60 and 90 days after manufacture) were determined by helium pycnometry 
(AccuPyc 1330, Micromeritics, USA) at 23±2 C (n=3). The expected densities of the 
extrudates, calculated from the densities of the starting materials weighted for their 
fractions in the formulations, allowed the calculation of the porosities of the 
extrudates (94). 
 
4.3.2.2.5. Mechanical characterization of extrudates 
Extrudates and co-extrudates (n=3) were characterized for mechanical 
properties at 1, 3, 8, 15, 30, 60 and 90 days after production, by a flexure test: a 
three-point bend rig test (TA.XT Plus, Stable Microsystems, UK) at perpendicular 
direction of extrusion. Force was applied to extrudates and both force and 
displacement were registered to allow calculation of the bending strength, stiffness, 
deformation and Young’s modulus of elasticity (97). 
 
4.3.2.2.6. Thermal behavior of extrudates 
The extrudates were evaluated for potential changes due to heat by 
differential scanning calorimetry (DSC, Q200, TA Instruments, USA). Samples (3.0-
6.0 mg, n=3) were placed in hermetic sealed aluminium pans and tested at 10 C/min 
(20-180 C). The enthalpies of fusion were found for each sample analyzed (1, 8, 30, 
60 and 90 days after manufacture) and for all starting materials. 
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4.3.2.2.7. Release of coumarin from extrudates 
The release of coumarin from extrudates was assessed by a 
dissolution test 30 days after production (Eur. Pharm., n=3, paddle method, 50 rpm, 
phosphate buffer, pH=6.8, AT7 Sotax, Switzerland) and samples quantified by UV 
spectroscopy at 307 nm (U-2000 Spectrophotometer, Hitachi, Japan). The efficiency 
of dissolution of coumarin was determined for all extrudates for characterizing the 
complete release of the drug (98). To provide a deeper understanding of the release 
of coumarin, the Korsmeyer-Peppas mathematical model was considered and 
applied separately to two periods of release (0-360 and 360-1440 min), as 360 min 
was the time point that better emphasized the differences on the drug release at the 
beginning and at the end of the process of dissolution. 
All statistical analysis was performed based on a one-way analysis of 
variance (ANOVA) with a 99% level of confidence and Tukey’s HSD test. Statistical 
significance was considered for p < 0.01. 
 
4.4.  Results 
 
4.4.1.  Extrusion profiles and force at steady state (FSS) 
The extrusion profiles registered when manufacturing all extrudates 
and co-extrudates presented the main features associated with a typical extrusion 
profile, namely the compression, the steady state flow and the forced flow phases 
(57). Formulations A and B (monolayers) also presented these features. Single layer 
extrudates (I to III) were easier to obtain than the multilayer ones (IV and V), and the 
higher the extrusion rate, the higher the FSS (Table 4.3). Looking at the FSS values 
one could observe the smoothness of the curves reflecting the ease of materials on 
extruding. 
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4.4.2.  Morphological evaluation of extrudates 
Visual inspection: All extrudates and co-extrudates were approved as 
no defects or surface irregularities were detected by visual inspection. Figure 4.2.A 
exemplifies an extrudate (formulation IV, A+B) with surface, length and width similar 
to the others manufactured. Additionally, it was not possible to distinguish any 
discontinuity line or irregularity between the different layers of extrudates IV and V 
(A+B, B+A+B, respectively). 
Scanning electron microscopy: Scanning electron microscopy (SEM) 
has shown that all extrudates presented smooth surfaces (only minor surface defects 
were detected at low magnifications), confirming the visual observations and the 
good quality of extrudates (Figure 4.2). 
 
 
 
 
Figure 4.2: Co-extrudate type A+B (a) after exiting the die (1) and after cut in a 
40x40x1.5 mm sample (2, insert not to scale), and SEM photos of sections of 
(B) single extrudate (extrudate II, A), (C) co-extrudate with two layers (extrudate 
IV, A+B) and (D) co-extrudate with three layers (extrudate V, B+A+B). 
 
  
 
Table 4.3: Extrusion force at steady state (Fss), thickness and enthalpies of fusion of extrudates, dissolution efficiency (after 960 min 
of release) and ‘n’ parameter and coefficients of determination (R2) obtained from the Korsmeyer-Peppas model. 
 
 Extrudates I Extrudates II Extrudates III Co-extrudates IV Co-extrudates V 
Fss (N)
 a,b
 2293 ± 37 
s
 3876 ± 126 
r
 4302 ± 116 
r
 9987 ± 287 
t
 21739 ± 419 
u
 
Thickness (mm) 
c
 1.51 ± 0.03 1.52 ± 0.03 1.53 ± 0.04 2.93 ± 0.03 2.94 ± 0.03 
Enthalpies of fusion 
(J/g) 
Day 1 160.9 131.9 128.0 116.8 142.4 
Day 8 154.3 152.1 149.8 148.1 133.3 
Day 30 150.3 130.6 149.2 153.8 142.6 
Day 60 146.4 139.4 142.4 148.9 139.3 
Day 90 146.3 158.8 147.4 137.1 132.2 
Dissolution efficiency 
(%) 
d
 
Day 1 41.3±1.0 
r,1
 42.0±0.8 
r,1
 41.0±1.6 
r,1
 24.2±0.6 
s,1
 14.9±0.2 
t,1
 
Day 3 40.9±0.4 
r,1
 41.9±1.1 
r,1
 41.2±0.4 
r,1
 24.6±2.2 
s,1
 14.8±0.2 
t,1
 
Day 8 39.6±0.9 
r,s,1
 42.0±0.4 
r,1
 38.4±0.5 
s,1,2
 24.7±1.2 
t,1
 14.3±0.3 
d,1,2
 
Day 15 40.1±0.4 
r,1
 39.9±0.2 
r,1,2
 38.6±0.4 
r,1,2
 22.9±0.9 
s,1
 12.9±0.4 
t,3
 
Day 30 39.5±1.0 
s,1
 36.5±0.2 
r,3
 38.6±0.6 
r,s,1,2
 23.9±0.7 
t,1
 14.0±0.2 
u,2
 
Day 60 40.0±0.6 
s,1
 36.5±1.2 
r,3
 36.4±1.5 
r,2
 22.4±0.8 
t,1
 12.5±0.1 
u,3
 
Day 90 36.8±0.4 
r,b,2
 38.3±0.6 
r,2,3
 35.5±0.5 
s,2
 23.0±0.2 
t,1
 12.3±0.2 
u,3
 
n 
(Korsmeyer-Peppas) 
0-360 min 0.65 ± 0.01 0.66 ± 0.01 0.67 ± 0.01 0.63 ± 0.01 0.99 ± 0.01 
360-1440 min 0.67 ± 0.02 0.66 ± 0.01 0.66 ± 0.01 0.56 ± 0.01 0.83 ± 0.01 
R
2 
(Korsmeyer-Peppas) 
0-360 min 0.999 ± 0.001 0.998 ± 0.001 0.999 ± 0.000 0.998 ± 0.000 0.999 ± 0.000 
360-1440 min 0.999 ± 0.000 0.999 ± 0.000 0.999 ± 0.000 0.998 ± 0.001 0.998 ± 0.000 
 
a
 n=3 
b
 The means of FSS with different letters in the indices are significantly different (ANOVA; p < 0.01; Tukey’s HSD; n = 3). 
c
 n=10 
d
 The means of dissolution efficiency with different letters in the indices (for each row) and the means of dissolution efficiency with different numbers in the indices (for each 
column) are significantly different (ANOVA; p < 0.01; Tukey’s HSD; n = 3). 
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The analysis of the SEM images showed that the identity of individual 
particles was not entirely lost, with some pores within the extrudates, suggesting that 
the melting of the particles did not happen. Also, the different layers of co-extrudates 
IV and V could be seen in Figure 4.2 (particularly 4.2.C and 4.2.D), which depicts a 
cross sectional cut of mono-, bi- and trilayer extrudates. 
 
4.4.3.  Physical characterization of extrudates 
 
4.4.3.1. Thickness 
The thicknesses of all mono-, bi- and trilayer extrudates have shown 
an increase of about 50% over the expected values (Table 4.3). Monolayer 
extrudates used the central chamber of the extruder (1 mm thick), whereas bi- and 
trilayer extrudates used other chambers (2 mm thick). The thicknesses were constant 
over time. 
 
4.4.3.2. Density and porosity 
All extrudates presented densities slightly lower than expected, which 
decreased over time, whereas the porosities increased over storage, with the 
exception of co-extrudate IV that presented a stable porosity from day 30 onwards 
(Figures 4.3 and 4.4). 
Co-extrudates V (three layers) have shown the highest density, 
whereas monolayer extrudates I and III (manufactured at 100 and 500 mm/min, 
respectively) were the less dense. The porosities presented reciprocal changes to 
densities. Furthermore, the density and porosity were not expected to be affected by 
eventual dissolution of one component in another because no volume reduction was 
observed, once all components of the formulation were mixed together. 
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Figure 4.3: Density of the extrudates over time 
from formulations I ( ), II ( ), III ( ), IV (X) and V ( ). 
 
 
 
 
 
Figure 4.4: Porosity of the extrudates over time 
from formulations I ( ), II ( ), III ( ), IV (X) and V ( ). 
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The changes observed were more evident in the first days after 
production, along with certain instability, but from day 30 onwards the variations on 
these properties were minimal, suggesting a stabilization of structures over time. 
Note: expected densities of 1.034 g/cm3 (extrudates from formulations 
I, II and III), 1.042 g/cm3 (extrudates from formulation IV) and 1.045 g/cm3 
(extrudates from formulation V) were considered for the calculation of porosity. 
 
4.4.3.3. Mechanical characterization 
The bending strength of extrudates and co-extrudates increased up to 
4-fold from day 1 to day 90 of storage (Figure 4.5): extrudates I, 0.20±0.00 to 
0.79±0.03 kPa; extrudates II, 0.22±0.01 to 0.94±0.02 kPa; extrudates III, 0.19±0.00 
to 0.84±0.06 kPa; extrudates IV, 0.26±0.00 to 1.07±0.05 kPa; extrudates V, 
0.21±0.01 to 0.93±0.03 kPa. 
Similarly, extrudates I (1.41±0.20 o 0.69±0.06 mm) presented the 
highest change on their deformation ability during storage, whereas extrudates II 
(1.10±0.13 to 0.62±0.05 mm) and III (1.22±0.18 to 0.66±0.05 mm) presented an 
intermediate shift and co-extrudates IV (0.78±0.06 to 0.48±0.04 mm) and V 
(0.81±0.21 to 0.47±0.06 mm) only a slight change (Figure 4.6). The overall decrease 
to half values of deformation reflects a stabilization of the products. The presence of 
one or more layers was reflected by a decrease on deformation, although direct 
relationships were hard to identify. After day 30 of storage, the changes observed 
were residual. 
There was a significant increase in the stiffness of co-extrudates IV 
and V (two and three layers) in the first 15 days after manufacture (2.16±0.13 to 
7.70±0.90 N/mm and 1.77±0.50 to 7.75±0.71 N/mm, respectively), comparing to 
extrudates I, II and III (one layer), in which the stiffness suffered a slight increase in 
the same period of storage (0.24±0.05 to 1.10±0.33 N/mm, 0.33±0.05 to 1.32±0.16 
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N/mm and 0.25±0.04 to 1.58±0.13 N/mm, respectively) before stabilizing over time 
(Figure 4.7). 
 
 
 
 
Figure 4.5: Bending strength of the extrudates over time 
from formulations I ( ), II ( ), III ( ), IV (X) and V ( ). 
 
 
 
 
Figure 4.6: Deformation of the extrudates over time 
from formulations I ( ), II ( ), III ( ), IV (X) and V ( ). 
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Figure 4.7: Stiffness of the extrudates over time 
from formulations I ( ), II ( ), III ( ), IV (X) and V ( ). 
 
 
 
 
 
Figure 4.8: Young’s modulus of elasticity of the extrudates over time from 
formulations I ( ), II ( ), III ( ), IV (X) and V ( ). 
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All extrudates and co-extrudates lost their elasticity over time (the 
Young’s modulus of elasticity increased). As expected, the highest shift on elasticity 
occurred in the first 15 days after manufacture (Figure 4.8). This loss of elasticity was 
higher for extrudates II (29.0±4.7 to 210.5±12.1 GPa). Extrudates I, III and IV 
presented an intermediate decrease of elasticity over storage (21.5±5.3 to 165±30.9 
GPa, 22.3±3.6 to 179.0±5.2 GPa and 25.0±1.6 to 165.4±17.1 GPa, respectively), 
whereas extrudates V had the lowest shift (20.0±5.4 to 146.3±16.7 GPa). 
To the author best knowledge, there are not comparative values for 
these properties to enable comparisons and the assessment of the quality of the 
extrudates. 
These patterns of modification for all mechanical properties were more 
evident and intense in the first days of storage until day 15, after which stabilization 
seems to have occurred. These results are in a reasonable agreement with the 
densities and porosities, whereby stabilization started between days 15 and 30 of 
storage. 
 
4.4.3.4. Thermal behavior 
Figure 4.9.A considers the thermal behavior of each starting material 
prior to manufacture for a better understanding of the thermal properties of the 
manufactured extrudates, as each material and its proportion in the formulation 
directly influences the thermal behavior of the final products. 
Extrudates and co-extrudates were analyzed over storage and 
presented modifications of thermal behavior (Figure 4.9.B-F), which were highlighted 
by different enthalpies of fusion over time (Table 4.3). It was neither possible to 
identify clear trends of increase / decrease of the enthalpies of fusion over time, nor 
directly correlate these results with other properties of the extrudates. However, it 
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was evident that changes of the mechanical properties, densities and porosities of 
the extrudates were concomitant with the changes observed in thermal behavior. 
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c) 
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e) 
 
 
 
 
f) 
 
 
Figure 4.9: Thermograms of the raw materials used in the study (a) and of the 
extrudates obtained from formulations I (b), II (c), III (d), IV (e) and V (f), 
analyzed over storage time.  
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4.4.3.5. Release of coumarin 
As anticipated, the release of coumarin from extrudates with one layer 
(I, II and III) was faster than from co-extrudates IV (two layers) and V (three layers), 
which presented the intermediate and the slowest release of coumarin, respectively 
(Figure 4.10). 
 
 
 
 
 
Figure 4.10: Drug release profiles obtained 30 days after manufacture of 
extrudates I ( ), II ( ), III ( ), IV ( ) and V ( ). 
 
 
 
The fractions of coumarin released after 24h of dissolution from 
extrudates stored for 30 days were higher for extrudates with one layer (I: 97.0±1.2 
%; II: 89.0±0.8 %; III: 96.3±2.2 %), by comparison to co-extrudates with two 
X
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(67.9±1.1 %) or three layers (53.1±0.1 %). The study considered the dissolution 30 
days after manufacture but the observations were similar for all other time points. 
For better characterizing the release of coumarin, the dissolution 
efficiencies (ratio between the area under the dissolution curve and the total area for 
a complete dissolution of coumarin) were considered. Table 4.3 summarizes the 
dissolution efficiencies for the different extrudates and times of storage. It was 
observed that the number of layers and the time of storage affected the release of 
coumarin: the higher the number of layers and the longer the time of storage is, the 
lower is the dissolution efficiency. 
The obtained release profiles were divided in two different regions: the 
initial phase of release (0-360 min) and the later period (360-1440 min). Different 
values calculated from the Korsmeyer-Peppas equation (Table 4.3) suggested that 
distinct mechanisms were governing the release of the drug simultaneously, with an 
emphasis of one over the others at the beginning (<360 min) followed by a change 
afterwards. 
In the first period (0-360 min), extrudates I to IV presented an 
intermediate n parameter of the Korsmeyer-Peppas model (0.63 to 0.67) suggesting 
that coumarin was released by a combination of two mechanisms: by diffusion and 
by changes in the structure of the extrudate, such as its relaxation , described as an 
anomalous transport / non-Fickian model (107). However, co-extrudates V presented 
a n parameter close to 1 (zero order). 
In the second period (360-1440 min), the mechanisms of release of 
coumarin from extrudates I to III (one layer) did not change (similar n parameters). 
However, it was detected a decrease in the n values calculated for extrudates IV 
(0.56) and V (0.83), suggesting changes in the mechanisms of release: coumarin 
was released from extrudates IV (bilayer) mainly by diffusion (n ≈ 0.5) and from 
extrudates V (trilayer) both by diffusion and by structural changes of the extrudates. 
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4.5.  Discussion 
Lipid-based excipients allow the manufacture of solid dosage forms in 
the absence of solvents and without changing the temperature during processing 
(61, 115). However, lipids present features that may affect the quality of the products, 
such as the existence of different polymorphic forms, leading to the most stable form 
on storage (42, 93). Also, in the majority of the cases, lipid-based materials are not 
pure substances but mixtures of different components, introducing a degree of 
uncertainty (with lack of predictability) on the properties of the extrudates. 
Additionally, it is well known that lipid-based materials undertake an aging 
phenomenon derived from the polymorphic changes of their particles (94) and/or due 
to structural variations (102). All these characteristics are relevant for understanding 
the behavior of solid dosage forms composed by such materials and for assessing 
the properties and quality of the manufactured extrudates. 
The formulations of this study were primarily composed by lipid-based 
materials (70%). One of the lipid materials used – glyceryl dibehenate – is composed 
of a mixture of mono (17.8%), di (53.0%) and tribehenate (26.8%) (data from the 
supplier). Also, the other lipids included in the formulations – polyethylene glycol 
glycerides and hard fat – were composed by saturated fatty acids with various 
carbon chain lengths (from 10 to 18 atoms of carbon). 
The extrudates (I, II and III) and co-extrudates (IV and V) when exiting 
the extrusion die in its final shape did not have their physical and mechanical 
properties stabilized, as described previously. As expected, the aging phenomenon 
observed for the lipid-based materials led to the occurrence of a similar aging 
process on the extrudates, especially reflected by the changes on their mechanical 
and calorimetric properties over storage (66). The different enthalpies of fusion 
registered over time proved that the products suffered physical changes after 
manufacture with an impact on the overall properties of the extrudates, which were 
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not stabilized right after extrusion but tended to stabilize over time. An additional 
accelerated stability study was conducted, in which the extrudates were stored at 
40±2 ºC and at 75±5 % of relative humidity, and the analysis of the thermal behavior 
of each extrudate confirmed these observations and trends. 
Therefore, the observed changes in the mechanical properties can be 
explained by these intrinsic characteristics of the starting materials: after extrusion, 
the lipid materials suffered changes due to polymorphic transformations, searching 
for the most stable molecular configuration, as discussed by San Vicente et al. (102). 
These molecular alterations resulted in stronger interactions between the particles of 
the extrudates and, therefore, in higher bending strengths and stiffnesses of the 
structures, as well as in a loss of elasticity and ability to deform. These changes 
occurred over the storage period and were more evident in extrudates I, II and III, 
when compared to co-extrudates IV and V. This was probably due to the lower 
mobility of the particles from the co-extrudates resulting from the higher forces at 
steady state registered during extrusion. Also, the molecular and structural changes 
of the extrudates justify the modifications observed for the density and porosity. Both 
the nature of the starting materials and their proportions in the formulations and the 
experimental conditions of the extrusion process affected the final properties of the 
extrudates and co-extrudates. 
The initial step of manufacture, in which the starting materials were 
mixed for obtaining a uniform extrudable mass (or masses), was successful, which 
was key for obtaining homogeneous products with consistent properties (66). All 
extrusion profiles presented the features expected when masses are homogeneous 
and adequate for extrusion. Also, both the increase of the extrusion rate and of the 
number of layers resulted in the increase of the Fss. The pressure of the extrudable 
masses on the walls of the die was more intense likely due to the higher impact of 
the particles on the surfaces of the extruder chambers and dies when applied higher 
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extrusion rates and, also, when two or three different extrudable masses are 
combined at the same region of the extruder. 
The steady state regions of the extrusion profiles testified the good 
quality of the extrusion process, as those areas were long and uniform, which was 
essential for achieving products of high quality. Also, the uniform and homogeneous 
surface features observed for all samples, without any detectable surface defect, 
testified the success of the mixing. Additionally, the observed homogeneous 
distribution of the materials throughout the extrudates (including the drug particles) 
was evident, which is relevant, as it prevents unwanted dissolution consequences 
(e.g. inappropriate release of the drug) (116). 
Similarly, the rate of extrusion considered had an impact on the flow of 
the extrudable masses through the extrusion chambers particularly at the exit of the 
die (108). It is well known that the masses are subjected to an intense pressure 
towards the walls of the extruder chambers and that, when exiting the die, the 
extrudates can suffer an expansion process (elastic recovery) in their structure, 
resulting in products with higher thicknesses than expected, when compared to the 
cross section of the dies (101). Therefore, the registered thicknesses of the 
extrudates were not surprising as they correspond to this structural expansion. Worth 
to point out that the expansion observed was similar for all extrudates and co-
extrudates (approximately 50 % of the die cross section) and did not compromise the 
surface quality. In a process of extrusion both materials and process affect the 
increase on extrudate thickness. But in the present research this was not observed. 
One can suggest that an increase on extrusion rate had an impact on the 
temperature of extruding materials locally with a decrease on their viscosity. The 
overall effect became independent of the process. Also, the low standard deviations 
obtained suggested that swelling of extruded materials was constant over time, 
which is certainly related to the materials rather than to the process conditions. This 
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increase of the dimensions / volume of the extrudates may also justify the changes of 
density and porosity over time, as there were not detected losses of mass over 
storage. 
It is important to mention that the flow of the different masses through 
the extrusion chambers and dies, especially when the same mass was extruded with 
different extrusion rates (comparison between extrudates I, II and III) or when two 
different masses were conveyed towards a single die (comparison between co-
extrudates IV and V), expectedly exert distinct forces at steady state. It suggests that 
the interaction between the particles of the starting materials occurred in different 
ways or extensions, depending on the extrusion rates and on the number of layers of 
the extrudates (69). However, this intimate interaction between the starting materials 
did not result in a complete loss of identity of the individual particles and, also, the 
applied extrusion forces did not result in a complete melting of the materials (117). 
One cannot exclude the fact that particles of materials with higher melting ranges 
remained in the solid state during the entire process or simply a poor heat transfer 
occurred. In this regard, cold extrusion seems to be closer to a granulation process 
than to a hot-melt extrusion. Also, the observation and identification of well-defined 
lines dividing the layers of co-extrudates IV and V suggested that the materials 
neither melt nor occurred a complete adhesion of the layers, as could be expected or 
desired, meaning that the melting did not occur or was incomplete at the point of 
merging the layers in the die. 
As referred previously, the mechanical properties registered and their 
changes over time were also different for all five formulations, even if the changing 
trends of the properties were comparable. Increasing extrusion rates resulted in 
increasing forces at steady state applied to the extrudable masses, which were 
pulled towards the walls of the extrusion chambers and die with higher intensities 
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and, at the same time, the particles of the raw materials interacted more intimately 
between each other. 
Also, the flow of a single extrudable mass through the extrusion 
apparatus can occur at simultaneous different speeds (27). In the laminar flow, the 
inner part of the extrudable masses, which is not in direct contact with the walls of 
the extrusion chambers or die, travels at a higher speed, when compared with the 
outer layers or portions of the mass, which interact with the surfaces of the extruder 
and suffer a decrease in the speed due to friction forces (101). These differences in 
the speeds of the masses have impact on the properties of the extrudates and on the 
stability of those properties. The higher the extrusion rate, the higher is the difference 
of extrusion speed of the inner and outer portions of the extrudable masses. 
Consequently, the stabilization of the structure of the extrudates can be increasingly 
compromised with the increase of the extrusion rate. For example, the sharkskin 
defect is well described and associated with the interaction of the extrudable masses 
and the walls / surfaces of the extruder. The higher the extrusion rate, the higher is 
the probability of occurring the sharkskin or other surface defects (69). In our case, 
the flow of the masses was adequate as there were not identified any surface 
defects. However, the differences of mechanical properties identified for extrudates I, 
II and III, which include the same materials and proportions but differ in the rate of 
extrusion, resulted from the phenomenon described before. 
The use of lipid-based materials as main components of the 
formulation also determined a retardation of the release of the drug, as referred in 
previous studies (61, 115). The matrices formed through the extrusion of these 
materials did neither dissolve nor disintegrate in the dissolution media and, therefore, 
the release of the drug took more time. Additionally, co-extrudates with two and three 
layers presented a physical barrier (single or double) to the release of coumarin as 
one of the layers of co-extrudates IV (the one without coumarin) and both outer 
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layers of co-extrudates V consisted of extra obstacles to the diffusion of coumarin, by 
increasing the distance of the drug particles to the dissolution medium. It was 
observed that the higher the number of layers, the slower the release of coumarin. 
Furthermore, the changes observed in the mechanical properties of 
the extrudates over time due modifications of the lipid-based materials and/or 
structural changes of the extrudates affected the release of the drug, reflected by 
changes on the dissolution efficiencies over storage, with a trend for decrease. The 
lower mobility of molecules in the structure of extrudates, reflected by increasing 
bending strengths and stiffnesses and decreasing elasticity and ability to deform, 
contributed to a progressive decrease of the dissolution efficiencies over time. The 
drug release profiles of all extrudates stored at 40±2 ºC and at 75±5 % of relative 
humidity (accelerated stability study) and registered at different time points confirmed 
these observations. 
According to the n parameter calculated from the Korsmeyer-Peppas 
model, the release of coumarin from extrudates I, II and III followed a combination of 
mechanisms throughout the entire dissolution: both the diffusion of coumarin from 
extrudates and structural modifications of the matrix contributed to the release. 
However, while the release of coumarin from extrudates IV followed the same 
combination of mechanisms in the first period of dissolution (0-360 min), the release 
occurred mainly due to the diffusion of coumarin rather than due to structural 
changes of the extrudates in the second period (360-1440 min). Also, the release of 
coumarin from extrudates V occurred mainly due to structural alterations of the 
extrudates such as relaxation in the first period of dissolution but in the second 
period, the release of coumarin was also due to the diffusion of coumarin from the 
matrix. Therefore, in the beginning of the study, the dissolution experimental 
conditions had an impact on the structure of the extrudates (which was not visually 
detected), which afterwards contributed to the release of coumarin. 
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4.6.  Conclusions 
This study has proved the possibility of successfully manufacturing 
extrudates and co-extrudates with a laminar shape, in the absence of solvents and 
without changing the temperature during processing. Additionally, the study proved 
the possibility of producing co-extrudates with more than one layer (two or three). 
The data generated proved that minor changes on both the processing 
conditions and fractions of raw materials in the formulations affected significantly 
their properties, particularly the release rate of coumarin. Furthermore, extrudates 
and co-extrudates composed by different layers (one, two or three) presented not 
only different release rates of the drug (the increase in the number of layers resulted 
in a decrease of the release rate) but also different release mechanisms over time. 
The assessment of the properties over storage revealed that all 
extrudates and co-extrudates presented good surface quality and adequate physical 
properties. However, these physical properties changed over time: the porosity, 
bending strength and stiffness increased, whereas the density, deformation and 
elasticity decreased, for all extrudates. This observed ageing effect was constant for 
each formulation allowing the consideration of these types of extrudates to increase 
the flexibility on tailoring the release of drugs and simultaneous delivery of non-
compatible drugs, by comparison to conventional dosage forms. 
 
 
  
 
 
 
  
  
 
 
 
 
 
 
 
 
CHAPTER 5 
 
 
 
Release of coumarin from laminar 
extrudates containing coumarin particles 
manufactured by RESS 
 
 
 
Adapted from: 
Influence of process variables on the properties of coumarin particles micronized by 
supercritical fluids (RESS) to be delivered in a laminar extrudate, G. Oliveira, J. F. 
Pinto, AAPS PharmSciTech (2015).  
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5.1.  Introduction 
Once the drug particles are manufactured, it is important to design 
delivery systems appropriate to carry, stabilize and deliver such particles without 
modifying their properties. 
As described in the previous chapters, the laminar extrusion of lipid 
based materials proved to be a promising technology for delivering drugs without 
affecting the characteristics of their particles. These extrudates are manufactured in 
the absence of solvents and without significant changes in temperature during 
processing and, by using low forces (i.e., low shear), help on keeping the original 
properties of the particles to be delivered. 
 
5.2.  Aim of study 
To assess the release of coumarin from laminar extrudates 
manufactured at room temperature and in the absence of solvents, containing 
particles of coumarin manufactured by RESS. 
 
5.3.  Materials and methods 
 
5.3.1.  Materials 
Laminar extrudates were prepared from glyceryl dibehenate 
(Compritol™ 888 ATO, Gattefossé, France), hard fat (Witocan™ 42/44, Sasol, 
Germany), a mixture of polyethylene glycol with glycerides (Gelucire™ 33/01, 
Gattefossé, France), a mixture of polydimethylsiloxane with silicon dioxide 
(Simethicone™ Q7-2243 LVA, Dow Corning, Belgium) and coumarin. 
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5.3.2.  Methods 
 
5.3.2.1. Preparation of laminar extrudates with coumarin 
The starting materials for each formulation of extrudate (Table 5.1) 
were weighted and mixed for 15 min in a planetary mixer (Kenwood Chef, UK). The 
mixtures were placed in the chamber of a ram extruder (Lurga, Portugal) with a die 
designed to prepare extrudates with laminar shape (1*40mm rectangular cross 
section). The extruder was adapted to a universal testing machine (LR 50K, Lloyds 
Instruments, UK) allowing recording of both force applied to the ram and its 
displacement during extrusion of materials. The extrusion force at steady state (Fss) 
was calculated as the mean value of data recorded between 80 and 140 mm 
displacement of the ram. Laminar extrudates were manufactured at a rate of 
300mm/min, cut into squares (40*40mm) immediately after production to facilitate 
their characterization and stored in a desiccator (23ºC / 30% RH). 
 
 
Table 5.1: Composition of the laminar extrudates. 
 
Materials 
Formulation (%) 
A B 
Polyethylene glycol glyceride 4 4 
Hard fat 33 33 
Glyceryl dibehenate 33 33 
Polydimethylsiloxane – silicon dioxide mixture 20 20 
RESS coumarin (obtained from Experiment 13 *) 10 - 
Milled coumarin - 10 
 
* See Chapter 2. 
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5.3.2.2. Characterization of materials and products 
The densities of the excipients before extrusion and of the extrudates 
(1, 3, 5, 8, 15, 30, 60, 90, 120, 150 and 180 days after manufacture) were 
determined by helium pycnometry (AccuPyc 1330, Micromeritics, USA) at room 
temperature (23±2 ºC) (n=3). The expected densities of extrudates were calculated 
from the densities of raw materials according to their fractions in the formulations. 
The porosities of extrudates were calculated from the densities of the extrudates, 
according to the following equation: 
 
                 
                
                   
       Eq. 5.1 
 
Extrudates were observed by naked eye for detection of surface 
defects through and after processing, and their thickness was measured at different 
regions with a caliper (n=10). The extrudates were also analyzed by scanning 
electron microscopy (SEM) and images of the surface and of cross section regions 
were obtained using a DSM 940 scanning electron microscope (Carl Zeiss, 
Germany). Samples were coated with gold in a sputter coater (E 5100, Bio-Rad, 
Germany). 
Laminar extrudates were tested for thermal behavior by differential 
scanning calorimetry (Q200, TA Instruments, USA). Samples (3-6 mg, n=3) were 
placed in hermetic sealed aluminium pans and tested at 10 ºC/min (heating intervals: 
60-80 ºC for particles; 20-180 ºC for extrudates). The enthalpies of fusion were 
calculated for each sample. The extrudates were tested over storage (1, 30, 90 and 
180 days). 
Extrudates were analyzed by X-ray diffractometry. Samples were 
mounted on an aluminium holder and analyzed in a Philips PW1730 diffractometer 
with automatic data acquisition (APD Philips v.35B). The diffractograms were 
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recorded at room temperature in the range 10°<2θ<35° and data collected in a 
continuous mode, with a step size of 0.015° (2θ) and an acquisition time of 1.5 
s/step. Extrudates were analyzed over storage (at 1, 30, 90 and 180 days). 
Extrudates (n=3) were tested for their mechanical properties (1, 3, 5, 
8, 15, 30, 60, 90, 120, 150 and 180 days after manufacture) by a three-point bend rig 
test (TA.XT Plus, Stable Microsystems, UK) at perpendicular direction of extrusion. 
Force was applied to extrudates and both force and displacement were recorded 
allowing calculation of bending strength, stiffness, deformation and Young’s modulus 
of elasticity. 
The release of coumarin from extrudates was studied through a 
dissolution test (Eur. Pharm., paddle method, 50 rpm, phosphate buffer, pH=6.8, AT7 
Sotax, Switzerland) at different time-points over storage (1, 30, 90 and 180 days), 
testing different parts of each extrudate (n=3). The coumarin released was quantified 
by UV spectroscopy at 307 nm (U-2000 Spectrophotometer, Hitachi, Japan). The 
Korsmeyer-Peppas mathematical model was applied to study the mechanisms of 
release of coumarin from extrudates. The model was applied to the first 16 h of 
dissolution. The dissolution efficiency was determined over storage time (1, 3, 8, 15, 
30, 60, 90, 120, 150 and 180 days) according to the following equation (98): 
 
    
  
 
 
    
       
         Eq. 5.2 
 
where y is the drug percent dissolved at time t. 
 
Analysis of data: data was analyzed by an ANOVA study (one-way 
analysis of variance) for a level of confidence of 99% and complemented by Tukey’s 
HSD test (statistical significance considered for p < 0.01). 
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5.4.  Results 
 
5.4.1.  Manufacture of extrudates 
Laminar extrudates containing either milled or RESS particles of 
coumarin presented similar extrusion profiles (Figure 5.1) and extrusion forces at 
steady state within the same range (Table 5.2). 
 
 
 
 
 
Figure 5.1: Extrusion profiles obtained after extruding formulation A ( ) and 
formulation B ( ). 
 
 
 
5.4.2.  Visual inspection of extrudates 
The visual inspection confirmed that the extrudates presented good 
surface characteristics, as the surface was smooth, regular and without defects, and 
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the distribution of the materials throughout the extrudates was visually homogeneous 
for both extrudates (Figure 5.2.A). 
SEM images captured from both extrudates confirmed the surface 
regularity and the absence of defects (Figure 5.2.B). Additionally, the SEM image of 
the cross section of the extrudate (Figure 5.2.C) revealed that at least some particles 
of the materials did not melt and did not lose their integrity. 
 
 
 
 
Figure 5.2: Photo of the laminar extrudate A after exiting the die and after being 
cut with 40x40 mm (a) and SEM photographs of the surface (b) and of a cross 
section (c) of extrudates A. 
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5.4.3.  Thickness of extrudates 
The thicknesses of extrudates were identical and homogeneous for 
each extrudate, approximately 50% thicker than the cross section of the die (Table 
5.2). 
 
5.4.4.  Density, porosity and mechanical properties of extrudates 
The density, porosity and mechanical properties of extrudates 
changed over storage: the density, deformation and elasticity decreased over time, 
whereas the porosity, bending strength and stiffness increased (Figure 5.3, A-F). 
These changes were more intense on the first days after manufacture but stabilized 
over time, especially from day 90, onwards. 
 
5.4.5.  Thermal behavior of raw materials and of extrudates over time 
The analysis over time of the thermal behavior confirmed the changes 
observed in the mechanical properties, density and porosity, as there were detected 
thermal behavior changes at different days after manufacture (Figure 5.4.A-B). Also, 
the enthalpies of fusion changed over time (Table 5.2). 
Extrudate A presented changes in the amorphous / crystalline content 
over storage as the X-rays diffractograms presented differences in the peak’s 
intensity at different days after manufacture (Figure 5.5.A). However, extrudate B 
presented identical X-rays diffractograms and there were not detected any changes 
in the intensity or diffraction angles of the peaks (Figure 5.5.B). For both extrudates, 
the peaks corresponding to the excipients were possible to identify, whereas the 
peaks of coumarin were not detected. 
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Table 5.2: Extrusion force at steady state (Fss), thickness, enthalpies of fusion 
and dissolution efficiency from extrudates (960 min of release, over storage). 
 
Extrudates A B 
Fss (N)
 a, b 4043 ± 336 r 3958 ± 165 r 
Thickness (mm) c 1.52 ± 0.03 1.54 ± 0.03 
Enthalpies of 
fusion (J/g) 
Day 
1 134.2 131.9 
8 147.8 152.1 
30 146.8 130.6 
60 141.4 139.4 
120 157.7 154.3 
180 154.9 149.3 
Dissolution 
efficiency (%) d 
Day 
1 42.7±1.8 r,1 42.0±0.8 r,1 
3 42.3±1.5 r,1 41.9±1.1 r,1 
8 39.6±1.0 r,1,2 42.0±0.4 r,1 
15 35.5±1.0 r,1,2 39.9±0.2 r,1,2 
30 35.3±0.8 r,1,2 36.5±0.2 r,3 
60 36.7±1.3 r,1,2 36.5±1.2 r,3 
90 39.5±1.3 r,1,2 38.3±0.6 r,2,3 
120 37.0±0.1 r,1,2 38.3±1.7 r,2,3 
150 34.4±0.9 r,1,2 37.4±0.9 s,2,3 
180 29.8±1.1 r,2 31.5±0.9 s,4 
 
a
 n = 3 
b
 The means of FSS with different letters in the indices are significantly different (ANOVA; p < 0.01; 
Tukey’s HSD; n = 3). 
c
 n = 10 
d
 The means of dissolution efficiency with different letters in the indices (for each column) and the 
means of dissolution efficiency with different numbers in the indices (for each row) are significantly 
different. (ANOVA; p < 0.01; Tukey’s HSD; n = 3). 
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e) 
 
 
 
 
f)  
 
 
Figure 5.3: Density (a), porosity (b), bending strength (c), deformation (d), 
stiffness (e) and Young’s modulus of elasticity (f) of laminar extrudates 
A ( ) and B ( ) over time of storage, with logarithmic fitting curves. 
 
[Expected densities of 1.028 g/cm
3
 (Formulation A) and 1.034 g/cm
3
 (Formulation B) 
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a) 
 
 
 
 
b) 
 
 
Figure 5.4: Thermograms of extrudates A (a) and B (b) analyzed over storage: 
1 ( ), 30 ( ), 90 ( ) and 180 ( ) days after manufacture. 
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a) 
 
 
 
 
b) 
 
 
Figure 5.5: X-ray diffractograms of extrudates A (a) and B (b) analyzed over 
storage: 1 ( ), 30 ( ), 90 ( ) and 180 ( ) days after manufacture. 
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5.4.6.  Release of coumarin from extrudates 
Coumarin was released almost completely in 24 h from both 
extrudates and in the same fashion (identical release profiles) (Figure 5.6). The 
dissolution efficiencies calculated at different time-points changed over storage 
(Table 5.2): in the first 120 days, the dissolution efficiencies of both extrudates were 
statistically equal, whereas in the second period (120-180 days) the dissolution 
efficiencies of extrudates B were higher and statistically different in comparison with 
extrudates A. Also, when comparing dissolution efficiencies of the same extrudate at 
different time-points over storage, there were statistical differences: for both 
extrudates there was a decreasing trend of dissolution efficiency over time. 
 
 
 
 
 
Figure 5.6: Drug release profiles obtained 90 days after manufacture of laminar 
extrudates A ( ) and B ( ). 
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The release of coumarin from extrudates was analyzed by considering 
the Korsmeyer-Peppas model. The n parameters of both extrudates – between 0.50-
0.75 (Table 5.3) – revealed a release of coumarin through different mechanisms. The 
n parameter calculated at day 1 was equal or close to 0.50 (ext. A: 0.54; ext. B: 
0.50). However, at days 30, 90 and 180, the calculated n parameter has shown 
values between 0.65-0.75. 
 
 
 
Table 5.3: Release exponents (n) and coefficients of determination (R2) 
obtained from the Korsmeyer-Peppas model (data considered within the 
interval 0-16 h). 
 
Day 
Extrudate A Extrudate B 
n R2 n R2 
1 0.54 ± 0.01 0.998 ± 0.001 0.50 ± 0.01 0.999 ± 0.000 
30 0.69 ± 0.02 0.998 ± 0.000 0.65 ± 0.01 0.998 ± 0.001 
90 0.71 ± 0.01 0.999 ± 0.000 0.67 ± 0.01 0.999 ± 0.000 
180 0.75 ± 0.01 0.998 ± 0.000 0.71 ± 0.01 0.999 ± 0.000 
 
 
When comparing the release of coumarin from extrudates 
manufactured with the same formulation but including different groups of coumarin 
particles – RESS or milled – the differences were not significant. 
 
5.5.  Discussion 
The particles manufactured by milling and RESS were incorporated in 
the extrudates for the assessment of the possibility of delivering the drug while 
preserving the physical properties of the particles. As the excipients in the 
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formulations for extrusion were the same and the properties of both groups of 
coumarin particles were not significantly different, it was not surprising that the 
processes of extrusion were also not different. The extrusion profiles, particularly the 
steady-state regions, justified the ability of both formulations in producing extrudates 
with high quality as ascertained by their properties. 
The changes of the mechanical properties observed over time for both 
extrudates were expected and had been previously described in the previous 
chapters (21). The observed increase of thickness occurred due to a limited elasticity 
of the materials right after the extrusion process when exiting the die. Additionally, 
some particles of the materials did not melt and did not lose their morphology, 
suggesting that the particles of coumarin might have been included in the matrix of 
extrudates without melting or losing their properties, as obtained after the different 
techniques of production. 
The manufactured extrudates have shown their ability to form a 
sustained release dosage form of coumarin. The different values for the n parameter 
(Korsmeyer-Peppas) obtained for the different releases suggested different 
mechanisms of release over time, which was already described previously. 
Firstly, the release of coumarin occurred mainly by Fickian diffusion 
from the matrix, which evolved over time to a combination of mechanisms of release: 
both Fickian diffusion of the drug from the matrix of extrudates concomitantly with 
structural changes of the matrix (98). This change of the mechanisms governing the 
release of coumarin from the extrudates were also in good agreement with the 
changes of the mechanical properties registered for the extrudates over time, 
particularly with the decrease of elasticity and increase of bending strength and 
stiffness, decreasing the ability of extrudates for releasing the coumarin. The 
resultant reduced mobility of the molecules in the extrudates matrices over time also 
justifies the decreasing of the dissolution efficiency over storage. 
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5.6.  Conclusions 
Laminar extrudates containing particles of coumarin micronized by 
RESS were successfully prepared to deliver the drug as a sustained release dosage 
form. Extrudates have shown adequate mechanical properties with little degree of 
aging over storage. 
 
 
 
  
 
 
 
  
  
 
 
 
 
 
 
 
 
CHAPTER 6 
 
 
 
Oral and transdermal delivery of drugs 
from laminar extrudates manufactured at 
room temperature and in the absence of 
solvents: an in-vitro study in excised skin 
and an in-vivo study in rats 
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6.1.  Introduction 
The manufacture of extrudates has been widely used in the 
pharmaceutical field, especially in the preparation of pellets for delivering drugs 
through the oral route of administration (42). However, it is possible to manufacture 
extrudates with other shapes (e.g. tubular or laminar) (60) allowing the extent of the 
use of extrudates to other applications, such as the delivery of drugs through the skin 
(topical or transdermal). 
Also, new ways of performing extrusion have been developed in 
alternative to the conventional processes: wet and hot-melt extrusion. Therefore, the 
development of an alternative extrusion procedure not requiring changes of 
temperature during processing and not involving solvents as starting materials, 
represents a step forward and an innovative way of performing extrusion. This opens 
the possibility of processing a higher number of drugs through extrusion, namely 
those that are sensitive to heat or change their properties in contact with solvents. 
Laminar extrudates and co-extrudates manufactured at room 
temperature and in the absence of solvents have proven their ability for carrying 
drugs that are released from the product in-vitro. However, do these drugs reach 
their target in order to activate the expected therapeutic effects? It is important to 
prove the extrudate’s ability for delivering drugs through specific routes of 
administration into their therapeutic targets. 
Coumarin and levothyroxine (free acid) have been used as model 
drugs. Coumarin has been referred as a therapeutic option for reducing tissue 
swelling due to disease or trauma (e.g. edema) and is also effective against protein 
lymphedemas (118). Additionally, coumarin has been tested in the treatment of 
certain types of cancer (91). Levothyroxine (free acid) is a drug commonly used for 
treating thyroid related affections, especially for the hormonal substitution therapies 
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for treating hypothyroidism. Therefore, levothyroxine is used for chronicle diseases, 
and is administered therapeutically in a daily basis (119). 
 
6.2.  Aim of study 
To assess the potential of laminar extrudates manufactured at room 
temperature and in the absence of solvents for delivering drugs through oral or 
transdermal routes of administration in rats and in excised human skin. 
 
6.3.  Materials and methods 
 
6.3.1.  Materials 
The laminar extrudates included glyceryl dibehenate (CompritolTM 888 
ATO, Gattefossé, France), hard fat (Witocan™ 42/44, Sasol, Germany), polyethylene 
glycol glycerides (Gelucire™ 33/01, Gattefossé, France) and a mixture of 
polydimethylsiloxane and silicon dioxide (Simethicone™ Q7-2243 LVA, Dow 
Corning, Belgium). Coumarin (0-90 μm) milled from coarse coumarin (Sigma-Aldrich, 
Germany) in an analytical grinder (A10 Yellow Line, IKA, Germany) and 
levothyroxine free acid (T4) (Peptido GmbH, Germany) used as purchased, were 
considered as model drugs. Table 6.1 summarizes the composition of the 
formulations used. 
 
6.3.2.  Methods 
 
6.3.2.1. Manufacture of laminar extrudates 
Extrudates were manufactured with a ram extruder (Lurga, Portugal) 
with a single chamber and a rectangular die (1x40mm cross section) designed to 
prepare extrudates with laminar shape. The extruder was adapted to a mechanical 
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press (LR 50K, Lloyds Instruments, UK) fit with a load cell allowing the collection of 
the force and displacement data from the process. The raw materials were mixed in 
a planetary mixer (Kenwood Chef, UK) for 15 minutes and fed manually into the 
extruder chamber. Extrudates were manufactured at an extrusion rate of 300 
mm/min and cut into squares (40x40x1mm) immediately after production and stored 
in desiccators (23 ºC / 30 % RH). 
 
 
Table 6.1: Composition of the laminar extrudates. 
 
Raw materials Formulation I (%) Formulation II (%) 
Glyceryl dibehenate 33 33 
Hard fat 33 33 
Polyethylene glycol glycerides 4 4 
Polydimethylsiloxane and silicon dioxide 20 20 
Coumarin (0-90 µm) 10 - 
Levothyroxine (free acid) - 10 
 
 
 
6.3.2.2. Characterization of laminar extrudates 
The extrusion procedure and formulations were equivalent to those 
previously developed and described in previous chapters. Therefore, the 
characterization of the extrudates was minimal and focused only the following 
properties: surface quality (visual examination); extrusion profiles and mean forces at 
steady-state (calculated as the mean of the single forces obtained between 70 and 
100 mm of displacement); thickness (measured with a caliper at different regions; 
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n=10); density (n=3) at room temperature (25±2 ºC) using a helium pycnometer 
(AccuPyc 1330, Micromeritics, USA); and porosity, calculated from the theoretical 
and apparent densities of extrudates: 
 
                 
                
                   
       Eq. 6.1 
 
Note: the theoretical densities of extrudates were calculated from the 
apparent densities of raw materials, according to their proportions in formulations. 
 
6.3.2.3. In-vitro permeation of coumarin and levothyroxine through 
excised skin 
The release of coumarin and levothyroxine from extrudates and its 
permeation through excised skin was studied in static vertical diffusion cells (Franz 
cells). The necessary pieces of human skin were collected from a healthy female 
with 54 years of age subjected to a surgical intervention to reduce abdominal mass, 
and after ethical approval and informed consent. 
The skin pieces were taken from the transportation package and 
submerged in isotonic phosphate buffer (pH 7.4) at approximately 60ºC and for 30 
seconds until thawed. The fat content was carefully removed and the stratum 
corneum (SC) gently separated from the remaining tissue. The SC was visually 
inspected for any defects and cut into sections large enough to fit on the Franz cells. 
The obtained SC pieces were then mounted between the donor and receptor 
compartments of the diffusion cells (permeation area: 1 cm2). 
As receptor media, there was used phosphate buffer (pH 6.8) for 
coumarin and a mixture of ethanol and water (1:1) for levothyroxine. The sink 
conditions were assured, the media were constantly stirred with a magnetic bar (200 
rpm) and the temperature maintained throughout the experiments (32±0.5 ºC). The 
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samples of extrudates (37 to 58 mg) were evenly applied on top of the SC (donor 
compartments), which were immediately sealed to prevent solvent evaporation. 
Tables 6.2 and 6.3 summarize the masses of coumarin and levothyroxine 
administered in each sample of extrudate. 
Samples (800 µl) were collected from the receptor compartments at 
several time points – 1, 2, 4, 8, 12 and 24 hours – and replaced with an equivalent 
amount of receptor medium. Coumarin was quantified by UV spectroscopy at 307 nm 
using a microplate reader (FLUOStar Omega, BMG Labtech, Germany), whereas 
levothyroxine was quantified by a solid phase chemiluminescent competitive 
immunoassay method (IMMULITE 2000 Canine Total T4; conversion factor: 1 nmol/L 
= 12.87 x 1 µg/dL) performed at DNAtech (Portugal). Repeated measures using six 
replicated cells were used. 
 
 
Table 6.2: Volume of receptor medium, doses of coumarin and T4 
delivered in each sample of extrudate. 
 
Diffusion cell nr. 
Volume of receptor 
medium (mL) 
Mass of coumarin 
administered (µg) 
Mass of T4 
administered (µg) 
1 4.3 4030 - 
2 4.8 3680 - 
3 4.4 3990 - 
4 4.3 4460 - 
5 4.7 4060 - 
6 4.3 4200 - 
7 3.6 - 4860 
8 3.6 - 4939 
9 3.6 - 4892 
10 3.6 - 5608 
11 3.8 - 5035 
12 3.7 - 5838 
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6.3.2.4. In-vivo delivery of levothyroxine 
There were used three groups of five randomly divided Wistar male 
rats (Charles River Laboratories, Spain) (Table 6.3). The rats were used after a 1-
week period of acclimatization to the laboratory. All experiments were carried out 
with permission of the local animal ethical committee and in accordance with the EU 
Directive 2010/63/UE and Portuguese legislation (Decreto-Lei 113/2003). The 
experimental protocol was approved by Direção Geral de Veterinária. 
 
 
Table 6.3: Groups of rats tested in-vivo and respective routes of 
administration. 
 
Group Rat nr. Route of administration 
A 1 – 5 Not applicable 
B 6 – 10 Transdermal 
C 11 – 15 Oral 
 
 
 
Rats of group A did not receive any levothyroxine (control group). Rats 
of group B were shaved and a single piece of extrudate was applied on the skin with 
the help of an adhesive. These rats were observed for 24 h in order to guarantee that 
the samples of extrudates remained in contact with the skin throughout the entire 
study. Rats of group C received 3 to 5 pieces of extrudates with the help of a gastric 
gavage. The weighs of the rats and the masses of samples of extrudates used, and 
the amounts of levothyroxine administered to each rat either through oral or 
transdermal routes are summarized in Table 6.4. 
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After 24 hours, animals were sacrificed and blood samples were 
collected by cardiac puncture. Levothyroxine was quantified as described in section 
6.3.2.3. 
 
 
 
Table 6.4: Weight of rats, masses of extrudates used in the in-vivo study, and 
doses of levothyroxine administered. 
 
Rat nr. 
Mass of rat 
(g) 
Mass of 
laminate (g) 
T4 administered 
Mass (µg) 
Mass of T4 per skin 
area (µg/cm2) 
1 253 - - - 
2 255 - - - 
3 264 - - - 
4 313 - - - 
5 268 - - - 
6 303 0.501 50083 12521 
7 302 0.496 49597 12399 
8 290 0.519 51880 12970 
9 282 0.505 50472 12618 
10 309 0.511 51116 12779 
11 318 0.024 2410 - 
12 285 0.022 2179 - 
13 310 0.020 2036 - 
14 294 0.018 1805 - 
15 314 0.024 2394 - 
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6.4.  Results and discussion 
 
6.4.1.  Manufacture of laminar extrudates 
The extrusion profiles (Figure 6.1) registered during the process of 
extrusion presented the typical features observed when the process originates 
extrudates with quality, which have been described extensively in the previous 
chapters. 
The registered mean extrusion forces at the steady state flow stage 
were respectively 4797±61 and 3950±69 N for formulations I and II. As both 
formulations were identical, differing only in the drug included, it was expected to 
obtain similar profiles and values of the mean extrusion forces at the steady state. 
Additionally, these extrusion profiles are also similar with the ones described in 
previous chapters and recorded for similar formulations (see chapters 3 and 4). 
 
6.4.2.  Characterization of laminar extrudates 
Both extrudates presented a good external appearance, starting with a 
homogeneous and smooth surface. There were not detected any surface 
imperfections nor structural defects such as fractures, variations of shape, excessive 
softness or brittleness. Therefore, the extrudates presented similar properties than 
the ones tested and characterized in the previous chapters (see chapters 3 and 4). 
Laminar extrudates I and II presented, respectively, thicknesses of 
1.52±0.03 and 1.54±0.03 mm, densities of 1.03±0.01 and 1.15±0.01 g/cm3, porosities 
of 0.3±0.1 and 0.4±0.2 %, given the theoretical densities of 1.03 and 1.16 g/cm3. 
All these observations confirm the quality of the extrudates used in the 
in-vitro and in-vivo studies. 
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Figure 6.1: Extrusion profiles of laminar extrudates I ( ) and II ( ). 
 
 
 
6.4.3.  In-vitro permeation of coumarin and levothyroxine through 
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Tables 6.5 and 6.6 summarize the total coumarin and total 
levothyroxine permeated through the excised skin during the diffusion tests. Both 
drugs were release by the laminar extrudates and crossed the excised skin (barrier), 
suggesting the suitability of laminar extrudates for delivering drugs through the skin 
(permeation). 
The data collected from all diffusion cells, confirmed that this diffusion 
/ permeation of coumarin and levothyroxine through the skin presents a high 
variability. For example, only 2 % of coumarin reached the receptor compartment in 
diffusion cell nr. 3, whereas up to 18 % of coumarin crossed the excised skin in 
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was not detected any drug at the receptor compartment of diffusion cell nr. 9 after 
24h, whereas up to 9.5 % of levothyroxine crossed the excised skin in diffusion cell 
nr. 8. 
 
Table 6.5: Total coumarin permeated in each diffusion cell over time. 
 
Diffusion cell nr. 1 2 3 4 5 6 
Total 
coumarin 
permeated 
(µg / %) 
1h 36 / 1 30 / 1 33 / 1 104 / 2 29 / 1 11 / 0 
2h 59 / 1 35 / 1 69 / 2 220 / 5 49 / 1 10 / 0 
4h 127 / 3 77 / 3 139 / 3 599 / 13 89 / 2 35 / 1 
8h 298 / 7 149 / 4 59 / 1 351 / 8 184 / 5 106 / 3 
12h 371 / 9 215 / 6 52 / 1 447 / 10 207 / 5 175 / 4 
24h 656 / 16 458 / 12 77 / 2 794 / 18 598 / 15 417 / 10 
 
 
Table 6.6: Total T4 permeated in each diffusion cell over time. 
 
Diffusion cell nr. 7 8 9 10 11 12 
Total T4 
permeated 
(µg / %) 
1h 4 / 0.1 9 / 0.2 ND ND 14 / 0.3 ND 
2h 50 / 1.0 85 / 1.7 ND ND 28 / 0.5 11 / 0.2 
4h 84 / 1.7 175 / 3.6 ND ND 24 / 0.5 21 / 0.4 
8h 147 / 4.3 288 / 5.8 ND 3 / 0.1 33 / 0.7 45 / 0.8 
12h 187 / 4.8 360 / 7.3 ND 9 / 0.2 52 / 1.0 59 / 1.0 
24h 207 / 5.0 470 / 9.5 ND 18 / 0.3 55 / 1.1 71 / 1.2 
 
ND = not detected (inferior to 2.95 µg / 0.1 %) 
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This high variability might be related with the region of the skin used 
for each of the diffusion cells, the integrity of the skin, and the ability of each drug for 
permeating lipid barriers, amongst other factors. 
The permeation was prolonged on time and, as referred previously, 
only small percentages of the drugs reached the receptor compartments. 
 
 
 
Table 6.7: Total levothyroxine (T4) quantified in rat’s plasma. 
 
Rat nr. 
Total T4 in plasma a 
(nmol/L) (µg/dL) (µg) (%) 
1 82 - - - 
2 83 - - - 
3 83 - - - 
4 86 - - - 
5 86 - - - 
6 892 69.3 10.4 0.02 
7 544 42.3 6.3 0.01 
8 616 47.9 7.2 0.01 
9 428 33.3 5.0 0.01 
10 524 40.7 6.1 0.01 
11 104 8.1 1.2 0.05 
12 664 51.6 7.7 0.36 
13 428 33.3 5.0 0.25 
14 94 7.3 1.1 0.06 
15 50 3.9 0.6 0.02 
 
a
 These values reflect the Total T4 permeated through skin and already subtract the physiological T4. 
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6. 4.4.  In-vivo delivery of levothyroxine 
The total levothyroxine (T4) quantified in the plasma of each group of 
study was summarized in Table 6.7. The rats from groups B and C presented levels 
of levothyroxine in plasma of 685±176 nmol/L and 352±268 nmol/L, which were 
significantly higher than the natural levels occurring in rats from the control group A 
(84±2 nmol/L). 
These results proved that levothyroxine could be successfully 
delivered in the blood mainstream through either routes of administration (oral or 
transdermal). 
 
6.5.  Conclusions 
Laminar extrudates manufactured at room temperature and in the 
absence of solvents successfully allowed the delivery of coumarin and levothyroxine 
through excised skin, proving the ability of these extrudates to carry particles of 
drugs for its delivery through the skin. Additionally, the same laminar extrudates 
allowed the delivery of levothyroxine to rats through both the oral and transdermal 
routes of administration, proving their potential for delivering drugs to the blood 
mainstream. 
 
 
 
  
 
 
 
 
 
 
 
 
CHAPTER 7 
 
 
 
Overall conclusions 
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7.1.  Summary of findings 
The bibliographic research and, especially, the laboratorial work 
undertaken during the concretization of this PhD project, produced a set of important 
findings that are here summarized: 
- The RESS technology allowed the manufacture of particles of 
coumarin with reduced sizes; 
- Both RESS operational modes – discontinuous and continuous – 
and the selection of the experimental conditions for each of the 
manufacturing procedures influenced the properties of the 
coumarin particles, especially their sizes and size distribution; 
- The processing conditions selected for each RESS experiment 
influenced the properties of the manufactured particles; 
- The extrusion procedure at room temperature and in the absence 
of solvents allowed the manufacture of laminar extrudates with 
good quality; 
- The manufactured extrudates successfully carried and released 
drugs, including particles of coumarin manufactured by RESS; 
- The laminar extrudates successfully delivered coumarin and 
levothyroxine through excised skin (in-vitro); 
- The laminar extrudates successfully delivered levothyroxine 
through oral and transdermal routes of administration (in-vivo). 
 
7.2.  Achievements 
Before beginning the laboratorial work, several objectives and outputs 
were identified as achievements to accomplish. As already described in the chapters 
of this thesis, the following objectives were achieved during this study: 
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- the manufacture of particles of coumarin with reduced sizes by 
RESS and its characterization; 
- the manufacture of laminar extrudates and co-extrudates in the 
absence of solvents and avoiding changes of temperature during 
processing, and their characterization; 
- the delivery of the manufactured drug particles with reduced sizes 
within the laminar extrudates prepared. 
 
7.3.  Verification of the hypothesis in study 
All the research and laboratorial work comprised in this thesis was 
developed with the aim of testing a hypothesis. The proposed hypothesis was “to 
produce laminar extrudates and co-extrudates, manufactured at room temperature 
and in the absence of solvents, containing particles of drugs processed by 
supercritical fluids”, in order to overcome some of the obstacles and challenges that 
permanently arise during the pharmaceutical development. 
After considering all these findings, which were accurately described 
in the previous chapters, it was observed that the work developed for both 
technologies – rapid expansion of supercritical solutions and extrusion in the 
absence of solvents and at room temperature – proved that the hypothesis is valid. 
 
7.4.  Added value 
All the work described in this thesis added value to the existing 
knowledge of the supercritical fluids and extrusion research areas. The findings and 
outputs described previsouly were innovative as there were explored two different 
possibilities for engineering or designing drug particles with specific properties via 
RESS and, additionally, a new way of performing the extrusion procedure avoiding 
changes of temperature during processing and eliminating the inclusion of solvents in 
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the formulations, as well as developing the laminar shape for the extrudates, 
representing a step forward in both fields of research. 
The experimental conditions selected for performing the extrusion 
procedure opened the possibillity for developing further applications, such as the 
delivery of thermo-sensitive drugs, in comparison to the hot-melt extrusion process, 
or the delivery of moisture / solvent sensitive drugs, in comparison to the wet 
extrusion procedure, or the manufacture of extrudates with a laminar shape, in 
comparison to the commonly used processes of manufacturing pellets. 
The reduction of energy consumed in the proposed extrusion 
procedure in consequence of the elimination of changes of temperature during 
processing, and the reduction of residual solvents in consequence of the elimination 
of the solvents from the formulations, could be considered as important contributions 
for developing new green technologies. 
 
 
  
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
FUTURE PERSPECTIVES 
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The scientific research is an activity that never ends. There will always 
be new theories, new challenges, and new ways of solving the problems. The 
curiosity of the humanity and the need of constant improvement continuously push 
the science forward. And the truth will only remain the truth until the moment when a 
“new truth” arises and replaces the existing knowledge. Thus, a scientific project is 
not the beginning and never the end. 
Therefore, the work developed in this PhD project, regardless of the 
findings described previously, can be considered as a starting point for new projects 
as it only addresses a part of the challenges facing the pharmaceutical development 
and consists of a small contribution for the knowledge in this field. 
In order to continue with this work and exploring new perspectives, it 
would be very interesting to explore the following areas: 
- Are there other materials suitable for inclusion in formulations for 
manufacturing extrudates with a laminar shape, at room 
temperature and without using any solvent? 
- It is possible to deliver two or more drugs using a single laminar 
extrudate? 
- It is possible to deliver the same drug with different release profiles 
using a single laminar extrudate? 
- Can the laminar extrudates be used for delivering drugs through 
another route of administration rather than the oral and the 
transdermal? 
There are relevant ways of continuing the work developed in this PhD 
project, contributing for building the knowledge in this field and transforming the 
laminar extrusion at room temperature and in the absence of solvents in a more 
relevant technique in the pharmaceutical development field. 
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